

Ron Waksman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4341594/publications.pdf>

Version: 2024-02-01

946
papers

37,551
citations

3721

89
h-index

4978

167
g-index

1204
all docs

1204
docs citations

1204
times ranked

21641
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years. <i>Cardiovascular Revascularization Medicine</i> , 2022, 38, 106-110.	0.3	11
2	Impact of Left Ventricular Outflow Tract Calcification on Outcomes Following Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 1-7.	0.3	6
3	Non-Culprit MACE Rate in LRP: The Influence of Optimal Medical Therapy Using DAPT and Statins. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 92-96.	0.3	2
4	Predicting future left anterior descending artery events from non-culprit lesions: insights from the Lipid-Rich Plaque study. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1365-1372.	0.5	2
5	Prosthetic valve endocarditis after transcatheter aortic valve replacement in <sc>lowâ€risk</sc> patients. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 896-903.	0.7	4
6	Longitudinal Distribution of Lipid-Rich Plaque in Nonculprit Lesions. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 168-170.	2.3	1
7	Transhepatic Access: Alternative Approach for Right Heart Catheterization and Pulmonary Angiography. <i>Cardiovascular Revascularization Medicine</i> , 2022, 40, 159-161.	0.3	1
8	Impact of Left Ventricular Outflow Tract Calcium on Hemodynamics and Outcomes in Patients After Transcatheter Aortic Valve Implantation With a Contemporary Self-Expanding Valve. <i>American Journal of Cardiology</i> , 2022, 168, 128-134.	0.7	1
9	Exploiting the Transformation Temperature to Reform an Infolded Nitinol Self-Expanding Peripheral Stent. <i>Journal of Endovascular Therapy</i> , 2022, , 152660282110687.	0.8	0
10	Overview of FDA Circulatory System Devices Panel virtual meeting on TriGUARD 3 cerebral embolic protection. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1789-1795.	0.7	3
11	Overview of the FDA's Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart â€ portable extracorporeal heart perfusion and monitoring system. <i>American Heart Journal</i> , 2022, 247, 90-99.	1.2	6
12	Coronary Artery Bypass at a Drug-Eluting Resorbable Magnesium Scaffold Site in a Porcine Model. <i>Cardiovascular Revascularization Medicine</i> , 2022, 42, 109-113.	0.3	2
13	Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. <i>Clinical Research in Cardiology</i> , 2022, 111, 795-805.	1.5	8
14	Postoperative myocardial injury and outcomes in liver and kidney transplant patients. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	6
15	TAVR for Low-Risk Bicuspid AorticâStenosis. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 533-535.	1.1	3
16	Vascular Closure: the ABCâ™s. <i>Current Cardiology Reports</i> , 2022, 24, 355-364.	1.3	3
17	Near-infrared spectroscopy predicts events in men and women: Results from the Lipid Rich Plaque study. <i>IJC Heart and Vasculature</i> , 2022, 39, 100985.	0.6	0
18	Implications of COVID-19 Vaccination on Hospital Encounters and Outcomes. <i>American Journal of Cardiology</i> , 2022, 170, 105-111.	0.7	3

#	ARTICLE	IF	CITATIONS
19	The Need for Additional Phenotyping When Defining Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 890-895.	1.1	1
20	High-definition intravascular ultrasound: current clinical uses. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 1213-1220.	0.2	4
21	Optical coherence tomography in coronary atherosclerosis assessment and intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 684-703.	6.1	106
22	A prospective, multicentre first-in-man study of the polymer-free ultrathin-strut BIOrapid stent (BIOVITESSE). <i>EuroIntervention</i> , 2022, 18, e132-e139.	1.4	1
23	Lipid-rich plaque density and low-density lipoprotein cholesterol in statin-treated versus statin-naïve patients: a post hoc analysis of the LRP study. <i>EuroIntervention</i> , 2022, 18, 91-93.	1.4	2
24	Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study. <i>EuroIntervention</i> , 2022, 18, e407-e416.	1.4	15
25	Clinical Experience of the PK Papyrus Covered Stent in Patients With Coronary Artery Perforations: Results From a Multi-Center Humanitarian Device Exemption Survey. <i>Cardiovascular Revascularization Medicine</i> , 2022, 43, 97-101.	0.3	7
26	Optical coherence tomography assessment of acute thrombogenicity at bifurcation sites using different stenting techniques: A porcine arteriovenous shunt study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	0
27	Sex Disparities in Hemodynamics and Outcomes in Patients Who Underwent Contemporary Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, 174, 101-106.	0.7	3
28	Incidence and Outcomes of Gastrointestinal Bleeding in Patients With Percutaneous Mechanical Circulatory Support Devices. <i>American Journal of Cardiology</i> , 2022, 174, 76-83.	0.7	2
29	Review of Late-Breaking Trials From CRT 2022. <i>Cardiovascular Revascularization Medicine</i> , 2022, 40, 3-7.	0.3	1
30	Cangrelor Use Patterns and Transition to Oral P2Y ₁₂ Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
31	Usefulness of Temporary Pacing in Patients With New Left Bundle Branch Block During Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
32	Impact of left ventricular outflow tract calcium on valve geometry in self-expanding transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 100, 404-412.	0.7	1
33	Correlation between lipidic content and arterial-wall plaque burden: A lipid rich plaque study sub-analysis. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
34	Small Vessel Coronary Artery Disease: Rationale for Standardized Definition and Critical Appraisal of the Literature. , 2022, 1, 100403.		3
35	Treatment of a Heavily Calcified Celiac Artery Ostial Subtotal Occlusion Using Shockwave Lithotripsy: A Novel Approach. <i>Cardiovascular Revascularization Medicine</i> , 2021, 25, 72-74.	0.3	3
36	Anatomical Characteristics Associated With Hypoattenuated Leaflet Thickening in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 1-6.	0.3	14

#	ARTICLE	IF	CITATIONS
37	Adverse Events and Modes of Failure Related to Rotational Atherectomy System: The Utility of the MAUDE Database. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 57-62.	0.3	4
38	Review of PCR e-Course 2020 Late-Breaking Clinical Trials. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 67-70.	0.3	0
39	Review of Structural Late-Breaking Trials From the TVT Connect 2020 and PCR e-Course 2020 Virtual Meetings. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 71-78.	0.3	2
40	Colossal left main to right atrium fistula ligation complicated by left circumflex STEMI. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1218-1220.	0.7	1
41	Micropuncture technique for femoral access is associated with lower vascular complications compared to standard needle. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1379-1385.	0.7	28
42	Detachment of an EluNIR Drug-Eluting Stent Spring Tip. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 98-99.	0.3	0
43	Intravascular ultrasound guidance in the evaluation and treatment of left main coronary artery disease. <i>International Journal of Cardiology</i> , 2021, 325, 168-175.	0.8	8
44	Utility of Routine Invasive Coronary Angiography Prior to Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 1-5.	0.3	4
45	Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy. <i>American Journal of Cardiology</i> , 2021, 142, 44-51.	0.7	1
46	Optical Coherence Tomography based treatment approach for patients with Acute Coronary Syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 141-149.	0.6	1
47	Cases of Early, Aggressive In-Stent Restenosis in Left Main Double Kissing (DK) Crush Technique and Treatment Options. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 90-94.	0.3	0
48	Reply: Transcatheter Aortic Valve Implantation During COVID-19 Pandemic: The Device Also Matters. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 68.	0.3	0
49	What Will 2021 Be Like?. <i>Cardiovascular Revascularization Medicine</i> , 2021, 22, 1-2.	0.3	0
50	The STRIATE-G Technique for COVID-19-Associated Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 345-346.	1.1	2
51	National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016. <i>American Heart Journal</i> , 2021, 231, 25-31.	1.2	8
52	Return of the Left Internal Mammary Artery. <i>Cardiovascular Revascularization Medicine</i> , 2021, 23, 119-120.	0.3	0
53	LAMPOON techniques to prevent or manage left ventricular outflow tract obstruction in transcatheter mitral valve replacement. <i>Annals of Cardiothoracic Surgery</i> , 2021, 10, 172-179.	0.6	16
54	Right transradial coronary angiography in the setting of tortuous brachiocephalic/thoracic aorta ("elephant head"): Impact on fluoroscopy time and contrast use. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	1

#	ARTICLE	IF	CITATIONS
55	Randomized Trial of Aspirin Versus Warfarin After Transcatheter Aortic Valve Replacement in Low-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009983.	1.4	33
56	<scp>Realâ€world</scp> experience of <scp>sutureâ€based</scp> closure devices: Insights from the <scp>FDA</scp> Manufacturer and User Facility Device Experience. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 572-577.	0.7	11
57	Rescue alcohol septal ablation for dynamic left ventricular outflow tract obstruction and haemodynamic collapse after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2021, 42, 2955.	1.0	0
58	Near-Infrared Spectroscopy Intravascular Ultrasound Imaging Evaluation in Patients With Chronic Renal Insufficiency. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1476-1478.	2.3	1
59	The vulnerable plaque detected: time to consider treatment. <i>Lancet, The</i> , 2021, 397, 943-945.	6.3	2
60	Clinical Impact and Predictors of Troponin Elevation in Patients With COVID-19. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 41-44.	0.3	11
61	Overview of the virtual 2020 FDA' s circulatory system devices advisory panel on Neovasc reducer system. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1152-1158.	0.7	2
62	Comparison of Characteristics and Outcomes of Patients With Acute Myocardial Infarction With Versus Without Coronarvirus-19. <i>American Journal of Cardiology</i> , 2021, 144, 8-12.	0.7	25
63	Pericardiocentesis induced right ventricular changes in patients with and without pulmonary hypertension. <i>Echocardiography</i> , 2021, 38, 752-759.	0.3	2
64	Prospective Evaluation of TMVR for Failed Surgical Annuloplasty Rings. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 846-858.	1.1	33
65	Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 859-872.	1.1	44
66	Balloon-Expandable Valve Geometry After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Bicuspid Versus Tricuspid Aortic Stenosis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 7-12.	0.3	7
67	A patient-level, pooled analysis of mortality rates with the Paseo-18 Lux paclitaxel drug-coated balloon in peripheral arterial disease. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 49-54.	0.3	1
68	Initial Findings From the North American COVID-19 Myocardial Infarction Registry. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1994-2003.	1.2	96
69	The impact of COVID-19 patients with troponin elevation on renal impairment and clinical outcome. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 45-48.	0.3	1
70	<scp>Propensityâ€matched</scp> comparison of <scp>largeâ€bore</scp> access closure in transcatheter aortic valve replacement using <scp>MANTA</scp> versus Perclose: A <scp>realâ€world</scp> experience. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 580-585.	0.7	11
71	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	1.0	80
72	Preventing Coronary Obstruction During Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 941-948.	1.1	55

#	ARTICLE	IF	CITATIONS
73	BASILICA Trial: One-Year Outcomes of Transcatheter Electrosurgical Leaflet Laceration to Prevent TAVR Coronary Obstruction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010238.	1.4	34
74	Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials. <i>American Heart Journal</i> , 2021, 235, 140-148.	1.2	14
75	Catheter Selection and Angiographic Views for Anomalous Coronary Arteries. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 995-1008.	1.1	14
76	Reasons for Screen Failure for Transcatheter Mitral Valve Repair and Replacement. <i>American Journal of Cardiology</i> , 2021, 148, 130-137.	0.7	12
77	Comparison of Quantitative Flow Ratio and Invasive Physiology Indices in a Diverse Population at a Tertiary United States Hospital. <i>Cardiovascular Revascularization Medicine</i> , 2021, 32, 1-4.	0.3	4
78	Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 62-67.	0.3	11
79	Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents. <i>Journal of the American Heart Association</i> , 2021, 10, e019815.	1.6	14
80	Overview of the Virtual 2021 FDA's Circulatory System Devices Advisory Panel on Lutonix 014 Drug-Coated Percutaneous Transluminal Angioplasty Catheter for Below-the-Knee Lesions in Critical Limb Ischemia. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 55-61.	0.3	3
81	High bleeding risk patients: one size does not fit all. <i>EuroIntervention</i> , 2021, 17, 189-191.	1.4	0
82	Pre-Operative Cardiovascular Testing before Liver Transplantation. <i>American Journal of Cardiology</i> , 2021, 152, 132-137.	0.7	3
83	The Impact of Aortic Angulation on Contemporary Transcatheter Aortic Valve Replacement Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1209-1215.	1.1	7
84	Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009960.	1.4	10
85	Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 149, 57-63.	0.7	0
86	Real-World Experience of the MANTA Closure Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 63-66.	0.3	5
87	Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients: Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 1-6.	0.3	6
88	Transcatheter Versus Surgical Aortic Valve Replacement in Young, Low-Risk Patients With Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1169-1180.	1.1	30
89	One-Year Outcomes After Treatment of Ostial In-Stent Restenosis in Left Circumflex Versus Left Anterior Descending or Right Coronary Artery. <i>American Journal of Cardiology</i> , 2021, 151, 45-50.	0.7	3
90	Review of Imaging and Physiology Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 71-75.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Review of Structural Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 76-81.	0.3	0
92	Transcatheter aortic valve replacement in low-risk patients: 2-year results from the LRT trial. American Heart Journal, 2021, 237, 25-33.	1.2	7
93	Treatment of Left Main Disease: Let the Patient Choose. Journal of the American Heart Association, 2021, 10, e021990.	1.6	3
94	Review of Late-Breaking Trials From CRT 2021 Virtual. Cardiovascular Revascularization Medicine, 2021, 28, 3-8.	0.3	0
95	Review of Coronary Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 65-70.	0.3	0
96	Percutaneous Management of a Saphenous Vein Graft Aneurysm With GraftMaster Covered Stents. Cardiovascular Revascularization Medicine, 2021, 28, 147-149.	0.3	0
97	Frequency of Lipid-Rich Coronary Plaques in Stable Angina Pectoris versus Acute Coronary Syndrome (from the Lipid Rich Plaque Study). American Journal of Cardiology, 2021, 158, 1-5.	0.7	1
98	Comparison of Outcomes in Patients With COVID-19 and Thrombosis Versus Those Without Thrombosis. American Journal of Cardiology, 2021, 160, 106-111.	0.7	4
99	Complications of Late-Presenting Myocardial Infarction in a COVID-19 Patient. Cardiovascular Revascularization Medicine, 2021, 29, 100-101.	0.3	0
100	Effect of Procedural Technique on Cardiovascular Outcomes Following Second-Generation Drug-Eluting Resorbable Magnesium Scaffold Implantation. Cardiovascular Revascularization Medicine, 2021, 29, 1-6.	0.3	9
101	High-Risk Percutaneous Coronary Intervention of Native Coronary Arteries Without Mechanical Circulatory Support in Acute Coronary Syndrome Without Cardiogenic Shock. American Journal of Cardiology, 2021, 158, 37-44.	0.7	1
102	Single-Center Experience With the LOTUS Edge Transcatheter Heart Valve. Cardiovascular Revascularization Medicine, 2021, 29, 85-88.	0.3	3
103	Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. American Heart Journal, 2021, 238, 59-65.	1.2	2
104	Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack. American Journal of Cardiology, 2021, 153, 129-134.	0.7	5
105	Review of Interventional Late Breaking Trials From AHA Scientific Sessions 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 29, 71-76.	0.3	0
106	Implications of Left Ventricular Function on Short-Term Outcomes in COVID-19 Patients With Myocardial Injury. Cardiovascular Revascularization Medicine, 2021, 29, 45-49.	0.3	5
107	Impact of Endothelial Shear Stress on Absorption Process of Resorbable Magnesium Scaffold: A BIOSOLVE-II Substudy. Cardiovascular Revascularization Medicine, 2021, 29, 9-15.	0.3	6
108	Greater plaque burden and cholesterol content may explain an increased incidence of non-culprit events in diabetic patients: a Lipid-Rich Plaque substudy. European Heart Journal Cardiovascular Imaging, 2021, . .	0.5	1

#	ARTICLE	IF	CITATIONS
109	Contemporary post-market adverse events and modes of failure related to VASCADE Vascular Closure System: The utility of the MAUDE database. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	3
110	Unprotected Left Main Percutaneous Coronary Intervention With or Without Hemodynamic Support. <i>American Journal of Cardiology</i> , 2021, 154, 29-32.	0.7	1
111	Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2228-2230.	1.1	2
112	Response by Khalid et al to Letter Regarding Article, "Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support". <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011275.	1.4	1
113	Lipid-rich plaques detected by near-infrared spectroscopy predict coronary events irrespective of age: A Lipid Rich Plaque sub-study. <i>Atherosclerosis</i> , 2021, 334, 17-22.	0.4	3
114	Evolution of Management and Outcomes of Patients with Myocardial Injury During the COVID-19 Pandemic. <i>American Journal of Cardiology</i> , 2021, 157, 42-47.	0.7	5
115	Impact of intravascular ultrasound on Outcomes following Percutaneous coronary intervention for In-stent Restenosis (iOPEN-ISR study). <i>International Journal of Cardiology</i> , 2021, 340, 17-21.	0.8	12
116	Valve-in-Valve for Failing Mitral Bioprosthesis With Tip-to-Base LAMPOON to Prevent Left Ventricular Outflow Tract Obstruction. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2021, 16, 409-413.	0.4	2
117	Outcomes After Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Anatomy. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2144-2155.	1.1	37
118	Comparison of plaque distribution and wire-free functional assessment in patients with stable angina and non-ST elevation myocardial infarction: an optical coherence tomography and quantitative flow ratio study. <i>Coronary Artery Disease</i> , 2021, 32, 131-137.	0.3	2
119	The new normal, CRT 2022, Colin Powell, and CRM journal growth. <i>Cardiovascular Revascularization Medicine</i> , 2021, 34, 1-2.	0.3	0
120	Scaffold thrombosis: what is to blame?. <i>EuroIntervention</i> , 2021, 17, e955-e957.	1.4	0
121	Impact of baseline imaging of non-culprit coronary lesions and adverse events: Insight from LRP study. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	1
122	Feasibility of a Porcine Arteriovenous Shunt Model for Assessment of Acute Thrombogenicity in Bifurcation Stenting Technique By Optical Coherence Tomography. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1000-1005.	0.3	2
123	Comparison of quantitative flow ratio value of left anterior descending and circumflex coronary artery in patients with Takotsubo syndrome. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 3-8.	0.7	3
124	Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 127-136.	0.3	13
125	Impact of Baseline Left Ventricular Diastolic Dysfunction in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020, 125, 258-263.	0.7	5
126	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , 2020, 219, 1-8.	1.2	27

#	ARTICLE	IF	CITATIONS
127	Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE III and BIOFLOW II trials. <i>International Journal of Cardiology</i> , 2020, 300, 60-65.	0.8	13
128	Resolution of Massive Intracoronary Thrombus During Percutaneous Coronary Intervention Utilizing Intensive Pharmacological and Aspiration Strategies. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 251-253.	0.3	0
129	Should Non-ST-Elevation Myocardial Infarction be Treated like ST-Elevation Myocardial Infarction With Shorter Door-to-Balloon Time?. <i>American Journal of Cardiology</i> , 2020, 125, 165-168.	0.7	7
130	Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis. <i>American Journal of Cardiology</i> , 2020, 125, 712-719.	0.7	5
131	Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality. <i>American Heart Journal</i> , 2020, 222, 112-120.	1.2	19
132	Impact of Intravascular Ultrasound on Outcomes Following Percutaneous Coronary Intervention in Complex Lesions (iOPEN Complex). <i>American Heart Journal</i> , 2020, 221, 74-83.	1.2	28
133	Apple Watch detecting high-grade block after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2020, 41, 1096-1096.	1.0	9
134	Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience Database for Patient- and Circuit-Related Adverse Events Involving Extracorporeal Membrane Oxygenation. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 230-234.	0.3	11
135	Transcatheter Aortic Valve Replacement After Prior Mitral Valve Surgery: Results From the Transcatheter Valve Therapy Registry. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1789-1796.	0.7	2
136	Real-World Experience of the Sentinel Cerebral Protection Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 235-238.	0.3	14
137	Impact of periprocedural biomarker elevation on mortality in stable angina pectoris patients undergoing elective coronary intervention: a systematic review and meta-analysis including 24,666 patients. <i>Coronary Artery Disease</i> , 2020, 31, 137-146.	0.3	5
138	Time-to-Event Meta-Analysis - Time to Do it Right!. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 692-693.	0.3	0
139	Procedural Outcomes of Patients Undergoing Percutaneous Coronary Intervention for De Novo Lesions in the Ostial and Proximal Left Circumflex Coronary Artery. <i>American Journal of Cardiology</i> , 2020, 135, 62-67.	0.7	9
140	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2635-2646.	1.2	209
141	COVID-19: Leave politics out of practicing medicine. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 937-938.	0.3	4
142	The Story is Not Yet "COMPLETE". <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 807.	0.3	0
143	Letter by Khalid et al Regarding Article, "The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support". <i>Circulation</i> , 2020, 142, e76-e77.	1.6	0
144	One Valve Type Does Not Fit All. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 931.	0.3	0

#	ARTICLE	IF	CITATIONS
145	Impact of Transcatheter Aortic Valve Replacement on Risk Profiles of Surgical Aortic Valve Replacement Patients. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 959-963.	0.3	3
146	Self-Expanding Transcatheter Aortic Valveâ€œFrame Infolding. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 789-790.	1.1	8
147	Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2467-2478.	1.1	27
148	The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: Study design and rationale. <i>American Heart Journal</i> , 2020, 228, 65-71.	1.2	25
149	Reply. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1834.	1.1	0
150	Concertina Effect: Incorporating Intravascular Imaging to Aid in Diagnosis. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1323-1324.	0.3	0
151	Clinical Implications of Physical Function and Resilience in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2020, 9, e017075.	1.6	11
152	In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1389-1390.	1.2	6
153	The DAEDALUS Study. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1390-1391.	1.2	0
154	Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1521-1531.	1.2	106
155	Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009189.	1.4	11
156	Risk of Coronary Obstruction and Feasibility of Coronary Access After Repeat Transcatheter Aortic Valve Replacement With the Self-Expanding Evolut Valve. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009496.	1.4	38
157	Cardiac safety research consortium â€œshock IIâ€œ think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , 2020, 230, 93-97.	1.2	14
158	Procedural Characteristics and Outcomes of Patients Undergoing Percutaneous Coronary Intervention During Normal Work Hours Versus Non-work Hours. <i>American Journal of Cardiology</i> , 2020, 135, 32-39.	0.7	1
159	Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Pre ² -HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 3062-3064.	1.2	5
160	Sutureless SAVR Versus TAVR for Symptomatic Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2655-2657.	1.1	2
161	Admissions Rate and Timing of Revascularization in the United States in Patients With Non-ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 134, 24-31.	0.7	17
162	Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2020, 135, 154-165.	0.7	7

#	ARTICLE	IF	CITATIONS
163	Review of CRT 2020 Late-breaking Trials. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 707-711.	0.3	1
164	MitraClip 30-Day Readmissions and Impact of Early Discharge: An Analysis from the Nationwide Readmissions Database 2016. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 954-958.	0.3	7
165	Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1343-1353.	1.1	68
166	Tip-to-Base LAMPOON to Prevent Left Ventricular Outflow Tract Obstruction in Valve-in-Valve Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1126-1128.	1.1	12
167	Treatment of ST-Segment Elevation Myocardial Infarction During COVID-19 Pandemic. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1024-1029.	0.3	20
168	Periprocedural Myocardial Injury: Pathophysiology, Prognosis, and Prevention. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1041-1052.	0.3	7
169	Review of ACC 2020 Late-Breaking Trials in Interventional Cardiology. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 905-911.	0.3	1
170	Guidelines for Balancing Priorities in Structural Heart Disease During the COVID-19 Pandemic. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1030-1033.	0.3	11
171	Swedish Coronary Angiography and Angioplasty Registry Score on Drug-Coated Balloons. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1379.	1.1	0
172	New Year and New Journal: Resolutions for 2020. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1.	0.3	0
173	Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 669-683.	6.3	76
174	Intravascular Lithotripsy Facilitated Percutaneous Endovascular Intervention of the Aortic Arch: A Single-Center Experience. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1006-1015.	0.3	9
175	Near-Infrared Spectroscopy Intravascular Ultrasound Imaging: State of the Art. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 107.	1.1	17
176	Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 700-701.	0.3	1
177	Association of Right Ventricular Longitudinal Strain with Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 452-460.	1.2	34
178	Coronary Artery Disease Assessed by Computed Tomography-Based Leaman Score in Patients With Low-Risk Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020, 125, 1216-1221.	0.7	5
179	Drug-Coated Balloon for De Novo Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1061-1073.	1.2	96
180	Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Bicuspid Aortic Valve Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1019-1027.	1.1	77

#	ARTICLE	IF	CITATIONS
181	The Orsiro Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stent: A Review of Current Evidence. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 540-548.	0.3	11
182	Risk of Mortality with Paclitaxel Drug-Coated Balloon in De Novo Coronary Artery Disease. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 549-555.	0.3	0
183	Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk. <i>American Journal of Cardiology</i> , 2020, 125, 1631-1637.	0.7	9
184	Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial. <i>Clinical Therapeutics</i> , 2020, 42, 649-660.e9.	1.1	12
185	Supporting evidence from optical coherence tomography for shortening dual antiplatelet therapy after drug-eluting stents implantation. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 261-267.	0.6	3
186	Coronary Heart Disease: Have We Reached a Plateau in Primary Prevention?. <i>Journal of the American Heart Association</i> , 2020, 9, e04963.	1.6	10
187	CRT 2020, COVID-19 and Beyond. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 705-706.	0.3	0
188	Percutaneous transcatheter release of stuck mechanical mitral valve leaflet. <i>European Heart Journal</i> , 2020, 41, 4072-4072.	1.0	5
189	Sustained Safety and Performance of the Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Pooled Outcomes of the BIOSOLVE-II and -III Trials at 3 Years. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1150-1154.	0.3	21
190	Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 726-735.	1.1	83
191	COVID-19 (SARS-CoV-2) and the Heart – An Ominous Association. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 946-949.	0.3	41
192	Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS) of the BIOSOLVE-II first-in-man trial. <i>EuroIntervention</i> , 2020, 15, e1375-e1382.	1.4	29
193	Adverse events with orbital atherectomy: an analytic review of the MAUDE database. <i>EuroIntervention</i> , 2020, 16, e325-e327.	1.4	15
194	Bioresorbable scaffolds: did we jump the gun?. <i>EuroIntervention</i> , 2020, 16, e103-e105.	1.4	2
195	Bioresorbable Scaffolds: Current Technology and Future Perspectives. <i>Rambam Maimonides Medical Journal</i> , 2020, 11, e0016.	0.4	19
196	NIRS-IVUS. <i>JACC: Cardiovascular Imaging</i> , 2020, 14, 1451-1453.	2.3	0
197	Abstract 16624: Gender Disparities Based on Time to Revascularization in the Treatment of Non-ST-segment Elevation Myocardial Infarction: An Analysis of 748,439 NSTEMI Admissions. <i>Circulation</i> , 2020, 142, .	1.6	0
198	Abstract 16040: High-risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support in Acute Coronary Syndrome. <i>Circulation</i> , 2020, 142, .	1.6	0

#	ARTICLE	IF	CITATIONS
199	Abstract 16677: Real World Screen Failure Rates for Transcatheter Mitral Valve Repair and Replacement for Mitral Regurgitation. <i>Circulation</i> , 2020, 142, .	1.6	0
200	Abstract 14527: Utility of Routine Invasive Coronary Angiography Prior to Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2020, 142, .	1.6	1
201	Abstract 17148: Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis: Two-Year Results From the LRT Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
202	Abstract 16860: Racial Disparity in COVID-19 Patients With Concomitant Myocardial Injury. <i>Circulation</i> , 2020, 142, .	1.6	0
203	Deoxyribonucleic Acid Repair Activity Is Associated with Healed Coronary Plaque Rupture by Optical Coherence Tomography. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 608-610.	1.1	1
204	Restenosis of Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007023.	1.4	158
205	Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007258.	1.4	87
206	Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2019, 124, 1020-1026.	0.7	11
207	Kissing Intravascular Lithotripsy Facilitated Endovascular Repair of a Complex Saccular Abdominal Aortic Aneurysm With Narrowed Distal Aorta. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, e97-e99.	1.1	8
208	Valve-in-Valve TAVR: State-of-the-Art Review. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2019, 14, 299-310.	0.4	40
209	Impact of two formulas to calculate percentage diameter stenosis of coronary lesions: from stenosis models (phantom lesion model) to actual clinical lesions. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 2139-2146.	0.7	3
210	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	1.1	366
211	The BASILICA Trial. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1240-1252.	1.1	183
212	Trends in Death Rate 2009 to 2018 Following Percutaneous Coronary Intervention Stratified by Acuteness of Presentation. <i>American Journal of Cardiology</i> , 2019, 124, 1349-1356.	0.7	7
213	Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. <i>Lancet, The</i> , 2019, 394, 1629-1637.	6.3	263
214	Durability and Clinical Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008155.	1.4	26
215	Relation of Sex and Race to Outcomes in Patients Undergoing Percutaneous Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2019, 123, 913-918.	0.7	14
216	Pacemaker Implantation and Dependency After Transcatheter Aortic Valve Replacement in the REPRISE III Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e012594.	1.6	48

#	ARTICLE	IF	CITATIONS
217	Intravascular Ultrasound Assessment of the Impact of Intravascular Lithotripsy. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1209-1210.	0.3	3
218	Predictors of 90-Day Readmission and in-Hospital Mortality in Takotsubo Cardiomyopathy: An Analysis of 28,079 Index Admissions. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 973-979.	0.3	16
219	Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019, 123, 1228-1238.	0.7	1
220	Impact of calcification on percutaneous coronary intervention: MACE Trial 1-year results. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 187-194.	0.7	36
221	Effect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaque on Optical Coherence Tomography—Review and Meta-Analysis. <i>Circulation Journal</i> , 2019, 83, 1480-1488.	0.7	22
222	OCT-Guided Treatment of Calcified Coronary Artery Disease: Breaking the Barrier to Stent Expansion. <i>Current Cardiovascular Imaging Reports</i> , 2019, 12, 1.	0.4	7
223	Letter by Khalid et al Regarding Article, “Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment Elevation Myocardial Infarction: A Pilot Study Using the Impella CP”. <i>Circulation</i> , 2019, 139, e1040-e1041.	1.6	11
224	Blinding results for transcatheter mitral valve repair. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 530.	0.3	1
225	Pulmonary cyclone: a case of large pulmonary arteriovenous malformation causing paradoxical coronary embolus treated with percutaneous closure device. <i>European Heart Journal</i> , 2019, 40, 1941-1941.	1.0	0
226	Expanding the Treatment of Calcified Lesions. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 622-623.	0.3	1
227	Left Bundle Branch Block After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1185-1187.	1.1	3
228	TAVR in Low-Risk Patients. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 901-907.	1.1	65
229	Cangrelor for the Rescue of Intra-Procedural Stent Thrombosis in Percutaneous Coronary Intervention. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 624-625.	0.3	1
230	Usefulness of Longitudinal Strain to Assess Remodeling of Right and Left Cardiac Chambers Following Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2019, 124, 253-261.	0.7	10
231	The Guardian Will Alert You Soon. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1928-1930.	1.2	0
232	Pre-Operative Cardiovascular Testing and Post-Renal Transplant Clinical Outcomes. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 588-593.	0.3	8
233	Adverse events and modes of failure related to the FilterWire EZ Embolic Protection System: Lessons learned from an analytic review of the FDA MAUDE database. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 157-164.	0.7	12
234	Usefulness of skeletal muscle area detected by computed tomography to predict mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis study. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1141-1147.	0.7	25

#	ARTICLE	IF	CITATIONS
235	Genetic and Nongenetic Implications of Racial Variation in Response to Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2019, 123, 1878-1883.	0.7	4
236	Techniques to Optimize the Use of Optical Coherence Tomography: Insights from the Manufacturer and User Facility Device Experience (MAUDE) Database. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 507-512.	0.3	14
237	Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis and Prior External Chest Radiation. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 376-380.	0.3	10
238	Adverse Events and Modes of Failure Related to Impella RP: Insights from the Manufacturer and User Facility Device Experience (MAUDE) Database. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 503-506.	0.3	29
239	CRM: The Next Milestone. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1.	0.3	0
240	Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanical vs Self-expanding Valves. <i>JAMA Cardiology</i> , 2019, 4, 223.	3.0	42
241	Adverse Events Associated with the Use of Guide Extension Catheters during Percutaneous Coronary Intervention: Reports from the Manufacturer and User Facility Device Experience (MAUDE) database. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 409-412.	0.3	29
242	First Report of Edge Vascular Response at 12â€”Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 392-398.	0.3	9
243	Reproducibility of Semi-automated Three-dimensional Volumetric Analysis using Cardiac Computed Tomography in Patients With Left Ventricular Assist Device. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 381-386.	0.3	1
244	Racial Disparities in Clinical Characteristics and Outcomes of Women Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1039-1042.	0.3	11
245	Dedicated Closure Device for Transcaval Access Closure. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2198-2206.	1.1	9
246	Hemodynamics and Subclinical Leaflet Thrombosis in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009608.	1.3	31
247	Safety and Feasibility of Performing Pericardiocentesis on Patients with Significant Pulmonary Hypertension. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1090-1095.	0.3	5
248	Was 2019 a Very Good Year?. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1037-1038.	0.3	0
249	Takotsubo syndrome: State-of-the-art review by an expert panel â€” Part 1. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 70-79.	0.3	71
250	Takotsubo syndrome: State-of-the-art review by an expert panel â€” Part 2. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 153-166.	0.3	42
251	Impact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: an optical coherence tomography analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 916-924.	0.5	13
252	Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1044-1051.	0.7	1

#	ARTICLE	IF	CITATIONS
253	A word of caution using self-expanding transcatheter aortic valve-frame infolding. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 555-558.	0.7	9
254	Spontaneous dissections involving multiple coronary arteries and a vertebral artery over 7 years. <i>European Heart Journal</i> , 2019, 40, 322-322.	1.0	2
255	Role of contractile reserve as a predictor of mortality in low-flow, low-gradient severe aortic stenosis following transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 707-712.	0.7	12
256	Comparison of coronary revascularization appropriateness for non-acute coronary syndrome cases under the 2017 update vs the 2012 appropriate use criteria. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 620-625.	0.7	0
257	Coronary perfusion pressure and left ventricular hemodynamics as predictors of cardiovascular collapse following percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 11-15.	0.3	5
258	Intravascular ultrasound-guided drug-eluting stent implantation. <i>Minerva Cardioangiologica</i> , 2019, 67, 306-317.	1.2	13
259	Adverse events and modes of failure related to the Impella percutaneous left ventricular assist devices: a retrospective analysis of the MAUDE database. <i>EuroIntervention</i> , 2019, 15, 44-46.	1.4	24
260	BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months. <i>EuroIntervention</i> , 2019, 15, e1006-e1013.	1.4	35
261	Reply to the letter to the editor "Impella device use in high-risk PCI". <i>EuroIntervention</i> , 2019, 15, 732-732.	1.4	2
262	Impact of Balloon Predilatation on Hemodynamics and Outcomes After Transcatheter Aortic Valve Implantation With the Self-Expanding CoreValve Prosthesis. <i>American Journal of Cardiology</i> , 2018, 121, 1358-1364.	0.7	3
263	Utility of Invasive Electrophysiology Studies in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2018, 121, 1351-1357.	0.7	40
264	Left main true bifurcation PCI: In the aftermath of DKCRUSH V trial: The case for modifying Medina terminology to include complexity of LMCA anatomy. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 137-138.	0.3	1
265	1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1841-1853.	1.2	288
266	Reduction of catheter kinks and knots via radial approach. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1141-1146.	0.7	14
267	MynxGrip® vascular closure device versus manual compression for hemostasis of percutaneous transfemoral venous access closure: Results from a prospective multicenter randomized study. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 418-422.	0.3	14
268	Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI "State-of-the-art review. <i>International Journal of Cardiology</i> , 2018, 264, 39-44.	0.8	2
269	Comparison of the Efficacy and Safety of Orbital and Rotational Atherectomy in Calcified Narrowings in Patients Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2018, 121, 934-939.	0.7	14
270	Utility of an additive frailty tests index score for mortality risk assessment following transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2018, 200, 11-16.	1.2	17

#	ARTICLE	IF	CITATIONS
271	Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 500-507.	1.6	14
272	In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris â€” DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial. <i>International Journal of Cardiology</i> , 2018, 255, 22-28.	0.8	54
273	Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 27.	3.8	135
274	Laser-Assisted Transcaval Access for Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, e3-e4.	1.1	4
275	Clinical Frailty as an Outcome Predictor After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2018, 121, 850-855.	0.7	43
276	Comparison of treatment strategies for femoroâ€”popliteal disease: A network metaâ€”analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1320-1328.	0.7	17
277	Temporal trends in patient referral for Transcatheter aortic valve replacement and reasons for exclusion at a high-volume Center in the United States. <i>American Heart Journal</i> , 2018, 196, 74-81.	1.2	4
278	Successful transcatheter aortic valve replacement in an oversized 800â€”mm ² annulus and bicuspid aortic valve. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 65-67.	0.3	3
279	In-Stent Restenosis of Drug-Eluting Stents Compared With a Matched Group of Patients With De Novo Coronary Artery Stenosis. <i>American Journal of Cardiology</i> , 2018, 121, 1512-1518.	0.7	19
280	Bioresorbable polymer drug-eluting stents â€” Authors' reply. <i>Lancet, The</i> , 2018, 391, 936-937.	6.3	0
281	Bioprosthesis leaflet thrombosis following self-expanding valve-in-valve transcatheter aortic valve replacement in patient taking factor Xa inhibitor and warfarin: A case report. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 29-32.	0.3	1
282	An amber signal lights up before the red: do not dismiss it. <i>European Heart Journal</i> , 2018, 39, 303-304.	1.0	2
283	Intraprocedural invasive hemodynamic parameters as predictors of short- and long-term outcomes in patients undergoing transcatheter aortic valve replacement. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 257-262.	0.3	3
284	Patient characteristics in variable left ventricular recovery from Takotsubo syndrome. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 247-250.	0.3	1
285	Intravascular ultrasound assessment of the effect of laser energy on the arterial wall during the treatment of femoro-popliteal lesions: a CliRpath excimer laser system to enlarge lumen openings (CELLO) registry study. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 345-352.	0.7	10
286	Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance: a meta-analysis. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 503-513.	0.7	30
287	A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 5-11.	0.3	18
288	Cardiogenic Shock Complicating Transcatheter Aortic Valve Replacement Due to Severe Para-Valvular Regurgitation. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 393-395.	0.3	2

#	ARTICLE	IF	CITATIONS
289	TCT-707 A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions â€œ BIOFLOW IV: 3 Year Clinical Results. Journal of the American College of Cardiology, 2018, 72, B283.	1.2	1
290	Emergent valve-in-valve transcatheter aortic valve replacement in patient with acute aortic regurgitation and cardiogenic shock with preoperative extracorporeal membrane oxygenator: A case report and review of the literature. Cardiovascular Revascularization Medicine, 2018, 19, 68-70.	0.3	9
291	Summary of the 2018 Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) for transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2018, 19, 964-970.	0.3	6
292	Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. Journal of the American College of Cardiology, 2018, 72, 3287-3297.	1.2	73
293	The Power of Imaging. JACC: Cardiovascular Interventions, 2018, 11, 2232-2233.	1.1	1
294	The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome. Cardiovascular Revascularization Medicine, 2018, 19, 912-916.	0.3	5
295	Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. Circulation: Cardiovascular Interventions, 2018, 11, e007331.	1.4	23
296	Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis. Journal of the American College of Cardiology, 2018, 72, 2095-2105.	1.2	175
297	Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach. Current Cardiology Reports, 2018, 20, 140.	1.3	14
298	Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery. American Journal of Cardiology, 2018, 122, 1652-1660.	0.7	53
299	Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves. American Journal of Cardiology, 2018, 122, 1536-1540.	0.7	0
300	Accuracy of predicted orthogonal projection angles for valve deployment during transcatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2018, 12, 398-403.	0.7	6
301	Clinical outcomes of complete revascularization using either angiography-guided or fractional flow reserve-guided drug-eluting stent implantation in non-culprit vessels in ST elevation myocardial infarction patients: insights from a study based on a systematic review and meta-analysis. International Journal of Cardiovascular Imaging, 2018, 34, 1349-1364.	0.7	6
302	Transcatheter Aortic Valve Replacement in Intermediateâ€•and Lowâ€•Risk Patients. Journal of the American Heart Association, 2018, 7, .	1.6	19
303	Left Main Revascularization. JACC: Cardiovascular Interventions, 2018, 11, 1244-1246.	1.1	3
304	Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12â€•month outcomes of <sc>BIOSOLVEâ€•I</sc> and <sc>BIOSOLVEâ€•II</sc>. Catheterization and Cardiovascular Interventions, 2018, 92, E502-E511.	0.7	48
305	Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine, 2018, 19, 971-975.	0.3	10
306	Predicted magnitude of alternate access in the contemporary transcatheter aortic valve replacement era. Catheterization and Cardiovascular Interventions, 2018, 92, 964-971.	0.7	12

#	ARTICLE	IF	CITATIONS
307	Stentless strategy in primary PCI setting: An alternative strategy in some clinical scenarios?. Cardiovascular Revascularization Medicine, 2018, 19, 5-7.	0.3	2
308	Letter by Dan et al Regarding Article, "Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial". Circulation: Cardiovascular Interventions, 2018, 11, e006679.	1.4	4
309	Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds. EuroIntervention, 2018, 14, e1040-e1048.	1.4	36
310	Impact of triggering event in outcomes of stress-induced (Takotsubo) cardiomyopathy. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 280-286.	0.4	43
311	Choice of Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Impacts Hemodynamics Differently According to Aortic Annular Size. American Journal of Cardiology, 2017, 119, 900-904.	0.7	41
312	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	1.2	47
313	The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale. American Heart Journal, 2017, 192, 98-104.	1.2	44
314	Intravenously Delivered Mesenchymal Stem Cells. Circulation Research, 2017, 120, 1598-1613.	2.0	142
315	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. American Journal of Cardiology, 2017, 119, 1135-1140.	0.7	5
316	Comparison of Propensity Score-Matched Analysis of Acute Kidney Injury After Percutaneous Coronary Intervention With Transradial Versus Transfemoral Approaches. American Journal of Cardiology, 2017, 119, 1507-1511.	0.7	11
317	Comparison of Baseline Characteristics and Inhospital Outcomes of Patients and Use of Bare Metal Versus Drug-Eluting Stents During Percutaneous Coronary Intervention 2005 to 2015 at a Single Tertiary Hospital. American Journal of Cardiology, 2017, 119, 1324-1330.	0.7	4
318	Contemporary transcatheter aortic valve replacement with third-generation balloon-expandable versus self-expanding devices. Journal of Interventional Cardiology, 2017, 30, 356-361.	0.5	40
319	Use of an ePTFE-covered nitinol self-expanding stent graft for the treatment off pre-closure device failure during transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2017, 18, 128-132.	0.3	15
320	Bioresorbable Scaffolds. JACC: Cardiovascular Interventions, 2017, 10, 1131-1133.	1.1	4
321	Correlates and Significance of Elevation of Cardiac Biomarkers Elevation Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 850-856.	0.7	9
322	CRT 2017 late-breaking trials. Cardiovascular Revascularization Medicine, 2017, 18, 304-307.	0.3	1
323	FDA Town Hall at CRT 2017: Current status and future endeavors in cardiovascular devices. Cardiovascular Revascularization Medicine, 2017, 18, 308-311.	0.3	0
324	Does the new generation of drug-eluting stents render bare metal stents obsolete?. Cardiovascular Revascularization Medicine, 2017, 18, 456-461.	0.3	11

#	ARTICLE	IF	CITATIONS
325	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponinâ€Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30
326	Feasibility of transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis: Rationale and design of the Low Risk TAVR (LRT) study. <i>American Heart Journal</i> , 2017, 189, 103-109.	1.2	24
327	ANTARCTIC: platelet function testing to adjust therapy. <i>Lancet, The</i> , 2017, 389, 1192-1193.	6.3	0
328	Outcome of implantation of a second selfâ€expanding valve for the treatment of residual significant aortic regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 673-679.	0.7	1
329	Labeling Stents/Scaffolds for Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 50-52.	1.1	2
330	Assessing strategies to improve patient management. <i>Nature Reviews Cardiology</i> , 2017, 14, 77-78.	6.1	2
331	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
332	Management and Outcome of Residual Aortic Regurgitation After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2017, 120, 632-639.	0.7	3
333	CRT: A multichannel educational event. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, S1.	0.3	0
334	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. <i>Lancet, The</i> , 2017, 390, 1843-1852.	6.3	214
335	Pre-Transcatheter Aortic Valve Replacement Right Bundle Branch Block. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1575-1577.	1.1	6
336	Effect of Bleeding Risk on Type of Stent Used in Patients Presenting With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2017, 120, 1272-1278.	0.7	6
337	Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 475-481.	0.3	9
338	Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	83
339	The State of the Absorb Bioresorbableâ€Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2349-2359.	1.1	55
340	Overview of the 2017 US Food and Drug Administration Circulatory System Devices Panel meeting on the Sentinel Cerebral Protection System. <i>American Heart Journal</i> , 2017, 192, 113-119.	1.2	12
341	High screen failure rate in patients with resistant hypertension: Findings from SYMPPLICITY HTN-3. <i>American Heart Journal</i> , 2017, 192, 76-84.	1.2	3
342	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2017, 69, 367-377.	1.2	405

#	ARTICLE	IF	CITATIONS
343	Society of Thoracic Surgeons Score Variance Results in Risk Reclassification of Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2017, 2, 455.	3.0	22
344	Does direct stenting with drug-eluting stents improve outcome? A meta-analysis of 10,900 patients. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 213-222.	0.7	8
345	A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 79-85.	0.3	28
346	Overview of the 2016 US Food and Drug Administration Circulatory System Devices Panel Meeting on the Amplatzer Patent Foramen Ovale Occluder. <i>American Journal of Cardiology</i> , 2017, 119, 153-155.	0.7	2
347	Promus Premier versus Xience V and Taxus Liberte in contemporary United States practice (REWARDS) Tj ETQq1 1 0,784314,rgBT /Over	0.3	2
348	Comparison of transradial and transfemoral access in patients undergoing percutaneous coronary intervention for complex coronary lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 640-646.	0.7	10
349	Impact of right ventricular function on outcome of severe aortic stenosis patients undergoing transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2017, 184, 141-147.	1.2	35
350	Crowdsourcing, a novel platform to generate scientific manuscripts, now in cardiology. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 555-556.	0.3	0
351	Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. <i>American Heart Journal</i> , 2017, 193, 35-45.	1.2	13
352	Diagnosis and management challenges of in-stent restenosis in coronary arteries. <i>World Journal of Cardiology</i> , 2017, 9, 640.	0.5	56
353	A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, e20-e24.	0.6	6
354	Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model. <i>EuroIntervention</i> , 2017, 13, 440-449.	1.4	55
355	Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. <i>EuroIntervention</i> , 2017, 13, 432-439.	1.4	98
356	Body mass index association with survival in severe aortic stenosis patients undergoing transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 118-124.	0.7	43
357	Review: Stent fracture in the drug-eluting stent era. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 404-411.	0.3	28
358	The influence of advancing age on implantation of drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 516-521.	0.7	9
359	The impact of prior stroke on the outcome of patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 322-327.	0.3	4
360	Impact of baseline mitral regurgitation on short- and long-term outcomes following transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2016, 178, 19-27.	1.2	14

#	ARTICLE	IF	CITATIONS
361	Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with <i>de novo</i> coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. <i>European Heart Journal</i> , 2016, 37, 2701-2709.	1.0	149
362	Impact of transfemoral versus transapical access on mortality among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 318-321.	0.3	19
363	How should we manage thrombosis of Viabahn stent-graft? A case report focused on catheter-directed thrombolysis. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 134-137.	0.3	1
364	Impact of Functional Versus Organic Baseline Mitral Regurgitation on Short- and Long-Term Outcomes After Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2016, 117, 839-846.	0.7	18
365	Intravascular ultrasound-guided drug-eluting stent implantation: An updated meta-analysis of randomized control trials and observational studies. <i>International Journal of Cardiology</i> , 2016, 216, 133-139.	0.8	73
366	Role of CMR in TAVR. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 593-602.	2.3	24
367	Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2050-2060.	1.2	340
368	Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1757-1764.	1.1	24
369	Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	79
370	Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 535-545.	0.3	12
371	Comparison in Men Versus Women of Co-morbidities, Complications, and Outcomes After Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. <i>American Journal of Cardiology</i> , 2016, 118, 1692-1697.	0.7	17
372	Bioresorbable scaffolds are here, please handle with care. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 353-354.	0.3	6
373	Drug-Coated Balloons: Seeking a Niche in the Treatment of Coronary Artery Disease. <i>Journal of Interventional Cardiology</i> , 2016, 29, 480-482.	0.5	0
374	Does the disparity in baseline characteristics of patients undergoing transcatheter aortic valve replacement with 23 mm vs. 26 mm valves impact clinical outcome?. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 176-182.	0.7	0
375	Learning curves for transfemoral transcatheter aortic valve replacement in the PARTNER trial: Success and safety. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 165-175.	0.7	67
376	Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis. <i>Journal of Interventional Cardiology</i> , 2016, 29, 108-112.	0.5	13
377	In-Stent Restenosis?. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	9
378	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	19

#	ARTICLE	IF	CITATIONS
379	The AngelMed Guardian system: Is there a role for implantable devices for early detection of coronary artery occlusion?. Cardiovascular Revascularization Medicine, 2016, 17, 522-527.	0.3	3
380	Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure. JACC: Cardiovascular Interventions, 2016, 9, 1259-1265.	1.1	56
381	Impact of restrictive versus obstructive pulmonary function patterns on mortality in patients undergoing transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2016, 17, 181-185.	0.3	6
382	A single center experience of Zilver PTX for femoro-popliteal lesions. Cardiovascular Revascularization Medicine, 2016, 17, 399-403.	0.3	5
383	Comparison of clinical outcomes with the utilization of monitored anesthesia care vs. general anesthesia in patients undergoing transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine, 2016, 17, 384-390.	0.3	34
384	Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Replacement With the Self-Expanding CoreValve Versus the Balloon-Expandable SAPIEN XT Valve. American Journal of Cardiology, 2016, 117, 1502-1510.	0.7	6
385	Learning curves for transapical transcatheter aortic valve replacement in the PARTNER-I trial: Technical performance, success, and safety. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 773-780.e14.	0.4	32
386	Ultrasound vs Angiography for Drug-Eluting Stent Implantation. JAMA - Journal of the American Medical Association, 2016, 315, 2469.	3.8	0
387	Multimodality imaging demonstrates trafficking of liposomes preferentially to ischemic myocardium. Cardiovascular Revascularization Medicine, 2016, 17, 106-112.	0.3	13
388	Trends in Complications and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 355-363.	1.1	72
389	Defining the non-vulnerable and vulnerable patients with computed tomography coronary angiography: evaluation of atherosclerotic plaque burden and composition. European Heart Journal Cardiovascular Imaging, 2016, 17, 481-491.	0.5	39
390	Learning curves for transfemoral transcatheter aortic valve replacement in the PARTNER-A trial: Technical performance. Catheterization and Cardiovascular Interventions, 2016, 87, 154-162.	0.7	61
391	Chemical Renal Denervation. JACC: Cardiovascular Interventions, 2016, 9, 599-601.	1.1	0
392	Vascular access in critical limb ischemia. Cardiovascular Revascularization Medicine, 2016, 17, 190-198.	0.3	11
393	Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Journal of the American College of Cardiology, 2016, 67, 603-613.	1.2	41
394	Clinical profiles and correlates of mortality in nonagenarians with severe aortic stenosis undergoing transcatheter aortic valve replacement. American Heart Journal, 2016, 173, 118-125.	1.2	20
395	Embolic Protection Devices in Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, e003284.	1.4	12
396	Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. International Journal of Cardiology, 2016, 205, 17-22.	0.8	28

#	ARTICLE	IF	CITATIONS
397	Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 12-24.	1.1	152
398	Frequency of Angina Pectoris After Percutaneous Coronary Intervention and the Effect of Metallic Stent Type. <i>American Journal of Cardiology</i> , 2016, 117, 526-531.	0.7	20
399	The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. <i>European Heart Journal</i> , 2016, 37, 536-545.	1.0	211
400	Cerebrovascular accidents after percutaneous coronary interventions from 2002 to 2014: Incidence, outcomes, and associated variables. <i>American Heart Journal</i> , 2016, 172, 80-87.	1.2	6
401	The influence of lipid-containing plaque composition assessed by near-infrared spectroscopy on coronary lesion remodelling. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 821-831.	0.5	15
402	Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. <i>Lancet</i> , The, 2016, 387, 31-39.	6.3	284
403	The adjunctive use of Angio-Seal in femoral vascular closure following percutaneous transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2016, 12, 88-93.	1.4	21
404	Magmaris preliminary recommendation upon commercial launch: a consensus from the expert panel on 14 April 2016. <i>EuroIntervention</i> , 2016, 12, 828-833.	1.4	64
405	Chipping of calcified plaques by orbital atherectomy systems, but holding approval tight: is the FDA moving faster than the European CE agency? A North American perspective. <i>EuroIntervention</i> , 2016, 12, 1083-1086.	1.4	0
406	Contemporary Use of Veno-Arterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Acute Coronary Syndrome. <i>Journal of Invasive Cardiology</i> , 2016, 28, 52-7.	0.4	20
407	Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 959-965.	2.3	3
408	Safety and long-term outcomes after percutaneous coronary intervention in patients with human immunodeficiency virus. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 192-198.	0.7	17
409	Outcome comparison of African-American and caucasian patients with severe aortic stenosis subjected to transcatheter aortic valve replacement: A single-center experience. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 640-647.	0.7	31
410	Will TAVR Become the Default Treatment for Patients With Severe Aortic Stenosis?—. <i>Journal of the American College of Cardiology</i> , 2015, 66, 122-124.	1.2	8
411	Prevalence and Impact of Pulmonary Hypertension on Patients With Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2015, 115, 1435-1442.	0.7	50
412	Reply. <i>American Journal of Cardiology</i> , 2015, 116, 494-495.	0.7	0
413	Prevalence and predictors of left atrial thrombus in patients with atrial fibrillation: is transesophageal echocardiography necessary before cardioversion?. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 12-14.	0.3	27
414	Overview of the Food and Drug Administration Circulatory System Devices Panel Meetings on WATCHMAN Left Atrial Appendage Closure Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 378-384.	0.7	39

#	ARTICLE	IF	CITATIONS
415	Delayed consent: will there be a shift in approach for US primary percutaneous coronary intervention trials?. <i>Lancet, The</i> , 2015, 386, 714-716.	6.3	3
416	Clinical outcomes of first- and second-generation drug-eluting stents in patients undergoing rotational atherectomy for heavily calcified coronary lesions. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 147-150.	0.3	16
417	Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. <i>Heart</i> , 2015, 101, 1309-1317.	1.2	40
418	Role of near-infrared spectroscopy in intravascular coronary imaging. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 299-305.	0.3	14
419	Analysis of Long-Term Survival Following Transcatheter Aortic Valve Implantation from a Single High-Volume Center. <i>American Journal of Cardiology</i> , 2015, 116, 256-263.	0.7	17
420	Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002232.	1.4	18
421	Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 84-89.	0.3	3
422	Rational use of rotational atherectomy in calcified lesions in the drug-eluting stent era: Review of the evidence and current practice. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 78-83.	0.3	20
423	Impact of Pre-Procedural Serum Albumin Levels on Outcome of Patients Undergoing Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2015, 115, 1260-1264.	0.7	38
424	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001441.	1.4	172
425	Embolic Protection Device for Saphenous Vein Graft Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002371.	1.4	5
426	Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Cangrelor. <i>American Journal of Cardiology</i> , 2015, 115, 1154-1161.	0.7	11
427	Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 151-155.	0.3	5
428	Prasugrel hydrochloride for the treatment of acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 585-596.	0.9	4
429	The choice of arterial access for percutaneous coronary intervention and its impact on outcome: An expert opinion perspective. <i>American Heart Journal</i> , 2015, 170, 13-22.	1.2	9
430	Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity. <i>American Journal of Cardiology</i> , 2015, 115, 716-723.	0.7	30
431	Outcome of Left-Sided Cardiac Remodeling in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2015, 116, 595-603.	0.7	19
432	Comparison of clinical outcomes in patients presenting with an acute coronary syndrome due to stent thrombosis or saphenous vein graft occlusion and undergoing percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 441-446.	0.3	2

#	ARTICLE	IF	CITATIONS
433	Intracoronary imaging: see more, better or worse?: Table 1. <i>European Heart Journal</i> , 2015, 36, 3356-3358.	1.0	4
434	Radial versus femoral access in patients presenting with acute coronary syndrome in the post-matrix era: Still one size does not fit all. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 435-436.	0.3	0
435	Comparison of Bleeding Outcomes After Percutaneous Coronary Intervention in Patients With Versus Without Aortic Stenosis. <i>American Journal of Cardiology</i> , 2015, 116, 1106-1109.	0.7	0
436	Response to Letter Regarding Article, "Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations". <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	0
437	Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 468-477.	0.7	40
438	Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. <i>American Heart Journal</i> , 2015, 169, 6-16.e6.	1.2	89
439	Impact of Blood Transfusions on Short- and Long-Term Mortality in Patients Who Underwent Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2015, 115, 93-99.	0.7	26
440	Intervention strategies for multi-vessel disease in patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2015, 179, 225-227.	0.8	13
441	Laser Atheroablation in Challenging Coronary Lesions. , 2015, , 97-102.		2
442	In-stent restenosis: local drug delivery with a stent or balloon?. <i>Journal of Thoracic Disease</i> , 2015, 7, 1691-2.	0.6	2
443	Clinical impact of second-generation everolimus-eluting stents compared with first-generation drug-eluting stents in diabetic patients undergoing multivessel percutaneous coronary intervention. <i>Journal of Invasive Cardiology</i> , 2015, 27, 263-8.	0.4	2
444	Comparison of Rotational Atherectomy, Plain Old Balloon Angioplasty, and Cutting-Balloon Angioplasty Prior to Drug-Eluting Stent Implantation for the Treatment of Heavily Calcified Coronary Lesions. <i>Journal of Invasive Cardiology</i> , 2015, 27, 387-91.	0.4	11
445	Safety and efficacy of everolimus-eluting stents compared with first-generation drug-eluting stents in patients undergoing primary percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 334-339.	0.3	0
446	Acquired thrombocytopenia after transcatheter aortic valve replacement: clinical correlates and association with outcomes. <i>European Heart Journal</i> , 2014, 35, 2663-2671.	1.0	71
447	Evaluation of the Edwards Lifesciences SAPIEN transcatheter heart valve. <i>Expert Review of Medical Devices</i> , 2014, 11, 553-562.	1.4	2
448	The Impact of Diabetes Mellitus on Long-Term Clinical Outcomes After Percutaneous Coronary Saphenous Vein Graft Interventions in the Drug-Eluting Stent Era. <i>Journal of Interventional Cardiology</i> , 2014, 27, 391-398.	0.5	6
449	Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 768-776.	1.4	56
450	Transfer distance effect on reperfusion: timeline of ST-elevation patients transferred for primary percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 369-374.	0.3	3

#	ARTICLE	IF	CITATIONS
451	Drug-coated balloon for peripheral arterial disease in the United States: a safe and effective landing zone. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 367-368.	0.3	0
452	Overview of the 2014 Food and Drug Administration Circulatory System Devices Panel meeting regarding the Lutonix® drug coated balloon. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 402-407.	0.3	4
453	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 162.	3.8	762
454	Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 1053-1060.	0.7	9
455	Editorial: Drug-Coated Balloon for Coronary Indications: Too Little, Too Late. <i>Journal of Interventional Cardiology</i> , 2014, 27, 580-581.	0.5	2
456	Aortic valve ChromaFlo®: A feasibility study of aortic regurgitation and effective annular aortic area assessment in a porcine model. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 156-159.	0.3	2
457	The new FDA reality. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 1-2.	0.3	9
458	C-reactive protein prior to percutaneous coronary intervention: Do we still need to check the lipid panel?. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 129-130.	0.3	0
459	The impact of live case transmission on patient outcomes during transcatheter aortic valve replacement: Results from the VERITAS study. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 63-68.	0.3	7
460	Use of emergency medical services expedites in-hospital care processes in patients presenting with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 219-225.	0.3	13
461	Stroke After Aortic Valve Replacement. <i>Circulation</i> , 2014, 129, 2245-2247.	1.6	9
462	Correlates for mortality in patients presented with acute myocardial infarct complicated by cardiogenic shock. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 13-17.	0.3	3
463	The dynamics of the coronary collateral circulation. <i>Nature Reviews Cardiology</i> , 2014, 11, 191-197.	6.1	80
464	Outcomes of Patients With Chronic Lung Disease and Severe Aortic Stenosis Treated With Transcatheter Versus Surgical Aortic Valve Replacement or Standard Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 63, 269-279.	1.2	99
465	Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Diabetes and Severe Aortic Stenosis at High Risk for Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1090-1099.	1.2	61
466	Editorial: Renal Sympathetic Denervation: A True Lack of Efficacy, or the Victim of a "Perfect Storm"?. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 61-62.	0.3	3
467	Left Atrial Appendage Occlusion. <i>Journal of the American College of Cardiology</i> , 2014, 63, 291-298.	1.2	72
468	Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 23-28.	0.3	8

#	ARTICLE	IF	CITATIONS
469	In vivo evaluation of axial integrity of coronary stents using intravascular ultrasound: Insights on longitudinal stent deformation. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 397-405.	0.7	10
470	Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 315-322.	0.3	13
471	Correlates and Outcomes of Late and Very Late Drug-Eluting Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1093-1102.	1.1	55
472	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31,379 patients. <i>Open Heart</i> , 2014, 1, e000064.	0.9	88
473	Coronary Blood Flow in Patients With Severe Aortic Stenosis Before and After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2014, 114, 1264-1268.	0.7	21
474	Current application and bioavailability of drug-eluting stents. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 689-709.	2.4	7
475	Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2014, 114, 1447-1455.	0.7	82
476	Superior survival with transcatheter core valve over surgery in high-risk patients with aortic stenosis: good news for the Heart Team. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 191-192.	0.3	0
477	Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?. <i>American Heart Journal</i> , 2014, 168, 545-551.	1.2	12
478	Definitions of Periprocedural Myocardial Infarction as Surrogates for Catheterization Laboratory Quality or Clinical Trial End Points. <i>American Journal of Cardiology</i> , 2014, 113, 1326-1330.	0.7	11
479	Relation of Preprocedural Assessment of Myocardial Contractility Reserve on Outcomes of Aortic Stenosis Patients With Impaired Left Ventricular Function Undergoing Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2014, 113, 1536-1542.	0.7	35
480	A Systematic Review and Collaborative Meta-Analysis to Determine the Incremental Value of Copeptin for Rapid Rule-Out of Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2014, 113, 1581-1591.	0.7	118
481	Bioresorbable scaffolds: rationale, current status, challenges, and future. <i>European Heart Journal</i> , 2014, 35, 765-776.	1.0	228
482	Incidence and correlates of major bleeding after percutaneous coronary intervention across different clinical presentations. <i>American Heart Journal</i> , 2014, 168, 248-255.	1.2	18
483	The Effects of Novel, Bioresorbable Scaffolds on Coronary Vascular Pathophysiology. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 413-425.	1.1	19
484	The Utility of Thrombus Aspiration for NSTEMI. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1125-1127.	1.2	2
485	A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 857-867.	1.1	223
486	Comparison of Outcomes After Percutaneous Coronary Intervention Among Different Coronary Subsets (Stable and Unstable Angina Pectoris and ST-Segment and Non-ST-Segment Myocardial) <i>Tj ETQq0 0 0 rgBTj0 Overlock 10 Tf 50 5</i>		

#	ARTICLE	IF	CITATIONS
487	Impact of Early Versus Late Clopidogrel Discontinuation on Stent Thrombosis Following Percutaneous Coronary Intervention With First- and Second-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2014, 113, 1968-1976.	0.7	19
488	Impact of Previous Coronary Artery Bypass Grafting on Patients Undergoing Transcatheter Aortic Valve Implantation for Aortic Stenosis. <i>American Journal of Cardiology</i> , 2014, 113, 1222-1227.	0.7	24
489	Operator learning curve for transradial percutaneous coronary interventions: implications for the initiation of a transradial access program in contemporary US practice. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 195-199.	0.3	21
490	Mortality in patients requiring pacemaker implantation following transcatheter aortic valve replacement: Insights from a systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2014, 174, 207-208.	0.8	14
491	Intra-stent tissue evaluation within bare metal and drug-eluting stents >3years since implantation in patients with mild to moderate neointimal proliferation using optical coherence tomography and virtual histology intravascular ultrasound. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 149-155.	0.3	6
492	Drug-eluting stents in patients on chronic hemodialysis: Paclitaxel-eluting stents vs. limus-eluting stents. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 86-91.	0.3	9
493	Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. <i>Atherosclerosis</i> , 2014, 233, 224-231.	0.4	25
494	Real-time, two-way interaction during ST-segment elevation myocardial infarction management improves door-to-balloon times. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 263-268.	0.3	1
495	Comparison of frequency and severity of longitudinal stent deformation among various drug-eluting stents: An intravascular ultrasound study. <i>International Journal of Cardiology</i> , 2014, 175, 261-267.	0.8	8
496	Safety of eptifibatide when added to bivalirudin during ST-segment elevation myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 278-283.	0.3	0
497	Design and rationale of the ANALYZE ST study: A prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients. <i>American Heart Journal</i> , 2014, 168, 424-429.e1.	1.2	5
498	Serial 2-Dimensional and 3-Dimensional Optical Coherence Tomography Assessment of Overhanging Struts of Drug-Eluting Absorbable Metal Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 575-576.	1.1	3
499	Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. <i>Atherosclerosis</i> , 2014, 235, 295-298.	0.4	3
500	Bioresorbable metal scaffold for cardiovascular application: Current knowledge and future perspectives. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 109-116.	0.3	39
501	Commercial Versus PARTNER Study Experience With the Transfemoral Edwards SAPIEN Valve for Inoperable Patients With Severe Aortic Stenosis. <i>American Journal of Cardiology</i> , 2014, 113, 342-347.	0.7	10
502	Optimal Intravascular Ultrasound Criteria for Defining the Functional Significance of Intermediate Coronary Stenosis: An International Multicenter Study. <i>Cardiology</i> , 2014, 127, 256-262.	0.6	27
503	Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. <i>Journal of Invasive Cardiology</i> , 2014, 26, 154-60.	0.4	3
504	Balloon aortic valvuloplasty for severe aortic stenosis as a bridge to transcatheter/surgical aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 632-637.	0.7	66

#	ARTICLE	IF	CITATIONS
505	Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 759-765.	0.7	7
506	Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. <i>Lancet, The</i> , 2013, 381, 836-844.	6.3	343
507	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013, 382, 1714-1722.	6.3	537
508	Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2013, 166, 266-272.	1.2	31
509	The Conundrum of Thrombus Aspiration: The TAPAS TASTE Sour. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 305-306.	0.3	3
510	Paravalvular regurgitation after transcatheter aortic valve replacement: Diagnosis, clinical outcome, preventive and therapeutic strategies. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 174-181.	0.3	17
511	FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study. <i>Journal of the American College of Cardiology</i> , 2013, 61, 917-923.	1.2	201
512	Sympathetic renal denervation: Hypertension beyond SYMPPLICITY. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 229-235.	0.3	13
513	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	1.2	807
514	In-stent restenosis of drug-eluting stents. <i>Future Cardiology</i> , 2013, 9, 721-731.	0.5	15
515	Second-generation Everolimus-eluting Stents Compared to First-generation Drug-eluting Stents in Patients Treated for Multivessel Disease. <i>Journal of Interventional Cardiology</i> , 2013, 26, 561-569.	0.5	4
516	Outcomes of concomitant percutaneous coronary intervention and balloon aortic valvuloplasty. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E835-41.	0.7	22
517	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Initially Treated with Fondaparinux: Results from an International, Multicenter, Randomized Pilot Study (SWITCH III). <i>Journal of Interventional Cardiology</i> , 2013, 26, 107-113.	0.5	28
518	IVUS-guided CTO-PCI. , 2013, , 67-77.		0
519	Asahi wires. , 2013, , 97-104.		0
520	A propensity score matched analysis to determine if second-generation drug-eluting stents outperform first-generation drug-eluting stents in a complex patient population. <i>International Journal of Cardiology</i> , 2013, 170, 43-48.	0.8	6
521	Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 76-80.	0.3	3
522	Two-Year Follow-Up of Outcomes of Second-Generation Everolimus-Eluting Stents Versus First-Generation Drug-Eluting Stents for Stenosis of Saphenous Vein Grafts Used as Aortocoronary Conduits. <i>American Journal of Cardiology</i> , 2013, 112, 61-67.	0.7	29

#	ARTICLE	IF	CITATIONS
523	Graft-Free surgical retroperitoneal vascular access as bail-out technique for failed percutaneous approach to transcatheter aortic valve replacement. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 23-26.	0.3	5
524	Innovation: A Key to Success in the Treatment of Cardiovascular Disease. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 121.	0.3	1
525	Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). <i>American Heart Journal</i> , 2013, 166, 421-428.e1.	1.2	71
526	Outcome Improvement for STEMI Patients: The Next Breakthrough in Interventional Cardiology?. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 1-2.	0.3	1
527	Safety and feasibility of performing staged non-culprit vessel percutaneous coronary intervention within the index hospitalization in patients with ST-segment elevation myocardial infarction and multivessel disease. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 258-263.	0.3	2
528	Radial access as a default for PCI: too early to call. <i>Lancet, The</i> , 2013, 382, 841-842.	6.3	3
529	Clinical Outcomes after Treating Acute Coronary Syndrome Patients with a Drug-Eluting Stent: Results from REWARDS-EMI (EndeavorÂ® for Myocardial Infarction Registry). <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 128-133.	0.3	7
530	Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1571-1576.	1.2	55
531	Drug-eluting Stents: Will the transformation to bioabsorption make durable polymers obsolete?. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 69-70.	0.3	2
532	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. <i>International Journal of Cardiology</i> , 2013, 167, 575-584.	0.8	160
533	Prevalence and Effect of Myocardial Injury After Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2013, 111, 1337-1343.	0.7	55
534	The state of the excimer laser for coronary intervention in the drug-eluting stent era. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 93-98.	0.3	53
535	Prognostic implications of percutaneous coronary interventions performed according to the appropriate use criteria for coronary revascularization. <i>Cardiovascular Revascularization Medicine</i> , 2013, 14, 316-320.	0.3	11
536	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 164-165.	1.2	0
537	Red cell distribution width as a bleeding predictor after percutaneous coronary intervention. <i>American Heart Journal</i> , 2013, 166, 104-109.	1.2	29
538	Safety and Efficacy of Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Women. <i>American Journal of Cardiology</i> , 2013, 111, 21-25.	0.7	3
539	Safety and Efficacy Outcomes of Overlapping Second-Generation Everolimus-Eluting Stents Versus First-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2013, 112, 1093-1098.	0.7	26
540	Prednisone: the last gasp of immunosuppressive therapy for restenosis prevention. <i>European Heart Journal</i> , 2013, 34, 1702-1704.	1.0	0

#	ARTICLE	IF	CITATIONS
541	Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin. Evidence-Based Medicine, 2013, 18, e30-e30.	0.6	0
542	Serial Observation of Drug-Eluting Absorbable Metal Scaffold. Circulation: Cardiovascular Interventions, 2013, 6, 644-653.	1.4	26
543	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, The, 2013, 347, f6530-f6530.	3.0	194
544	Optimal Revascularization Strategies for Percutaneous Coronary Intervention of Distal Anastomotic Lesions after Coronary Artery Bypass Surgery. Journal of Interventional Cardiology, 2013, 26, 366-371.	0.5	2
545	Acute closure after stenting. Catheterization and Cardiovascular Interventions, 2013, 82, 765-767.	0.7	1
546	Tips and tricks of the CART technique. , 2013, , 198-205.		0
547	Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy. Catheterization and Cardiovascular Interventions, 2013, 82, 614-620.	0.7	1
548	Distal anastomotic lesions after coronary artery bypass surgery: Incidence, pathogenesis, and treatment approach. Catheterization and Cardiovascular Interventions, 2013, 81, 1162-1168.	0.7	1
549	The independent value of a direct stenting strategy on early and late clinical outcomes in patients undergoing elective percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 81, 949-956.	0.7	1
550	Ischemic colitis after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2013, 81, 1067-1071.	0.7	1
551	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. International Journal of Cardiology, 2013, 167, 575-584.	0.8	87
552	Bioresorbable drug-eluting magnesium-alloy scaffold: design and feasibility in a porcine coronary model. EuroIntervention, 2013, 8, 1441-1450.	1.4	84
553	Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study. EuroIntervention, 2013, 8, 1006-1011.	1.4	78
554	Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. EuroIntervention, 2013, 9, 613-619.	1.4	79
555	Beta radiation for renal nerve denervation: initial feasibility and safety. EuroIntervention, 2013, 9, 738-744.	1.4	18
556	Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the Edwards SAPIENâ„¢ Transcatheter Heart Valve. Circulation, 2012, 125, 550-555.	1.6	26
557	Clinical Outcomes and Treatment After Drug-Eluting Stent Failure. Circulation: Cardiovascular Interventions, 2012, 5, 12-19.	1.4	22
558	Response to Letter by Weimar and Knipp Regarding Article, "Patients With Severe Asymptomatic Carotid Artery Stenosis Do Not Have a Higher Risk of Stroke and Mortality After Coronary Artery Bypass Surgery". Stroke, 2012, 43, .	1.0	0

#	ARTICLE	IF	CITATIONS
559	Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2012, 163, 1031-1036.	1.2	131
560	Hypothermia Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 197-210.	1.2	100
561	Chronic Total Occlusion Recanalization. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 116-117.	1.1	1
562	Paclitaxel Drug-Coated Balloons. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1001-1012.	1.1	81
563	The Appropriate Use of Risk Scores—Editorials published in <i>JACC: Cardiovascular Interventions</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Interventions</i> or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1106-1107.	1.1	1
564	Outcomes of Patients With Severe Aortic Stenosis at High Surgical Risk Evaluated in a Trial of Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2012, 110, 1008-1014.	0.7	21
565	Percutaneous Coronary Intervention With Second-Generation Paclitaxel-Eluting Stents Versus Everolimus-Eluting Stents in United States Contemporary Practice (REWARDS TLX Trial). <i>American Journal of Cardiology</i> , 2012, 110, 1119-1124.	0.7	11
566	Transcatheter aortic valve replacement under monitored anesthesia care versus general anesthesia with intubation. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 207-210.	0.3	57
567	Utilization of intravascular ultrasound to accurately position stents in true aorto-ostial lesions. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 353-356.	0.3	2
568	Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver [®] PTX [®] Drug-Eluting peripheral stent. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 281-285.	0.3	5
569	Back to atheroablation: renaissance or déjà vu?. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 205-206.	0.3	0
570	The impact of intra-aortic balloon counter-pulsation on in-hospital mortality in patients presenting with anterior ST-elevation myocardial infarction without cardiogenic shock. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 328-330.	0.3	12
571	Qualitative comparison of coronary angiograms between 4 french catheters with an Advanced Cardiovascular Injection System and 6 french catheters with manual injection. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 843-848.	0.7	4
572	Retroperitoneal hemorrhage after percutaneous coronary intervention in the current practice era: Clinical outcomes and prognostic value of abdominal/pelvic computed tomography. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 29-36.	0.7	22
573	A novel, minimally invasive access technique versus standard 18-gauge needle set for femoral access. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1180-1185.	0.7	39
574	In vivo comparison of a polymer-free Biolimus A9 eluting stent with a biodegradable polymer-based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 429-436.	0.7	14
575	Impact of Diabetes Mellitus on Long-term Clinical Outcomes of Patients on Chronic Hemodialysis after Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2012, 25, 147-155.	0.5	8
576	Bifurcation stenting: the current state of play. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 51-57.	0.3	0

#	ARTICLE	IF	CITATIONS
577	Alcohol septal ablation in hypertrophic obstructive cardiomyopathy. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 72-74.	0.3	0
578	Giant saphenous vein graft aneurysm treated with covered stent. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, e1-e2.	0.3	2
579	Fluoroscopy use and left anterior descending artery angiography to guide transapical access in patients with prior cardiac surgery. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 106-110.	0.3	2
580	Clinical and silent stroke following aortic valve surgery and transcatheter aortic valve implantation. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 133-140.	0.3	18
581	Intravascular ultrasound lumen area parameters for assessment of physiological ischemia by fractional flow reserve in intermediate coronary artery stenosis. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 177-182.	0.3	49
582	Rebuttal to: Inappropriate use of risk score models for operative mortality in nonsurgical treatments by Luc Noyez, MD, PhD. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 184.	0.3	0
583	CRT 2012 welcomed former President Bill Clinton. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 75-76.	0.3	0
584	Too Early to Call. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 157-158.	0.3	3
585	Comparison of Outcome of Higher Versus Lower Transvalvular Gradients in Patients With Severe Aortic Stenosis and Low (<40%) Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2012, 109, 1031-1037.	0.7	35
586	Safety and Efficacy of the XIENCE V Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice. <i>American Journal of Cardiology</i> , 2012, 109, 1288-1294.	0.7	30
587	Saphenous Vein Graft Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 831-843.	1.1	116
588	Polymer drug-eluting stents: is the future biodegradable?. <i>Lancet, The</i> , 2011, 378, 1900-1902.	6.3	11
589	Cellular Video-Phone Assisted Transmission and Interpretation of Prehospital 12-Lead Electrocardiogram in Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2011, 24, 112-118.	0.5	11
590	Integrilin in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2011, 24, 351-356.	0.5	13
591	Clinical Profile, Prognostic Implication, and Response to Treatment of Pulmonary Hypertension in Patients With Severe Aortic Stenosis. <i>American Journal of Cardiology</i> , 2011, 107, 1046-1051.	0.7	111
592	Changes in Mitral Regurgitation After Balloon Aortic Valvuloplasty. <i>American Journal of Cardiology</i> , 2011, 108, 1777-1782.	0.7	14
593	Platelet reactivity in diabetic patients subjected to acute exercise stress test. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 20-24.	0.3	3
594	The use of excimer laser for complex coronary artery lesions. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 69.e1-69.e8.	0.3	25

#	ARTICLE	IF	CITATIONS
595	Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovascular Revascularization Medicine, 2011, 12, 312-322.	0.3	40
596	Editorial Note. Cardiovascular Revascularization Medicine, 2011, 12, 1.	0.3	12
597	Safety and efficacy of drug-eluting stents and bare metal stents in acute coronary syndrome. Cardiovascular Revascularization Medicine, 2011, 12, 385-390.	0.3	5
598	Editorial Note. Cardiovascular Revascularization Medicine, 2011, 12, 73-74.	0.3	2
599	Comparison between Society of Thoracic Surgeons Score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2011, 12, 345-349.	0.3	75
600	First in the US: can early cardiovascular device evaluation be revived in the US?. Cardiovascular Revascularization Medicine, 2011, 12, 195-196.	0.3	1
601	Winners and losers from the cessation of the Cypher and Nevo stent programs. Cardiovascular Revascularization Medicine, 2011, 12, 269-270.	0.3	0
602	From TAVI to TAVR: transforming imagination into reality. Cardiovascular Revascularization Medicine, 2011, 12, 343-344.	0.3	4
603	Outcomes of patients with acute myocardial infarction from a saphenous vein graft culprit undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2011, 78, 23-29.	0.7	27
604	Comparison of closure strategies after balloon aortic valvuloplasty: Suture mediated versus collagen based versus manual. Catheterization and Cardiovascular Interventions, 2011, 78, 119-124.	0.7	24
605	Covered stents for coronary perforations. Catheterization and Cardiovascular Interventions, 2011, 78, 246-253.	0.7	52
606	Current status, challenges and future directions of drug-eluting balloons. Future Cardiology, 2011, 7, 765-774.	0.5	9
607	Correlation between fractional flow reserve and intravascular ultrasound lumen area in intermediate coronary artery stenosis. EuroIntervention, 2011, 7, 225-233.	1.4	69
608	The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroIntervention, 2011, 7, 705-710.	1.4	75
609	In vivo virtual histology intravascular ultrasound comparison of neointimal hyperplasia within drug-eluting- versus bare metal stents. Journal of Invasive Cardiology, 2011, 23, 262-8.	0.4	5
610	Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2010, 75, 86-92.	0.7	27
611	Does Black Ethnicity Influence the Development of Stent Thrombosis in the Drug-Eluting Stent Era?. Circulation, 2010, 122, 1085-1090.	1.6	46
612	Outcome of Undersized Drug-Eluting Stents for Percutaneous Coronary Intervention of Saphenous Vein Graft Lesions. American Journal of Cardiology, 2010, 105, 179-185.	0.7	54

#	ARTICLE	IF	CITATIONS
613	Safety and In-Hospital Outcomes of Bivalirudin Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 297-301.	0.7	17
614	Clinical Profile, Treatment Assignment and Clinical Outcome of Patients With Severe Aortic Stenosis Not Eligible to Participate in a Clinical Trial of Percutaneous Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2010, 105, 857-861.	0.7	6
615	Three-Year Outcomes Following Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in an Unselected Population With Coronary Artery Disease (from the REWARDS Registry). <i>American Journal of Cardiology</i> , 2010, 106, 504-510.	0.7	14
616	A Novel Percutaneous Coronary Intervention Risk Score to Predict One-Year Mortality. <i>American Journal of Cardiology</i> , 2010, 106, 641-645.	0.7	8
617	Correlates and Consequences of Gastrointestinal Bleeding Complicating Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 106, 1069-1074.	0.7	19
618	Patient selection and risk assessment and anatomical selection criteria for patients undergoing transfemoral aortic valve implantation. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 124-136.	0.3	15
619	Editorial Note. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 139.	0.3	0
620	Editorial Note. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 217.	0.3	0
621	A further word of caution before using the internal mammary artery for coronary revascularization in patients with severe peripheral vascular disease!. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 195-201.	0.7	10
622	Combined mechanical and pharmacological approach to a thrombus-containing lesion. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 972-976.	0.7	2
623	Does on-versus off-hours presentation impact in-hospital outcomes of ST-segment elevation myocardial infarction patients transferred to a tertiary care center?. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 484-490.	0.7	10
624	Complications and Outcome of Balloon Aortic Valvuloplasty in High-Risk or Inoperable Patients. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1150-1156.	1.1	237
625	Correlates and Causes of Death in Patients With Severe Symptomatic Aortic Stenosis Who Are Not Eligible to Participate in a Clinical Trial of Transcatheter Aortic Valve Implantation. <i>Circulation</i> , 2010, 122, S37-42.	1.6	100
626	Decline in platelet count in patients treated by percutaneous coronary intervention: definition, incidence, prognostic importance, and predictive factors. <i>European Heart Journal</i> , 2010, 31, 1079-1087.	1.0	43
627	Biodegradable and Bioabsorbable Stents. <i>Current Pharmaceutical Design</i> , 2010, 16, 4041-4051.	0.9	60
628	Drug-Eluting Stents: Issues of Late Stent Thrombosis. <i>Cardiology Clinics</i> , 2010, 28, 97-105.	0.9	24
629	Synergistic increase risk of death and myocardial infarction at one year in patients with concomitant diabetes mellitus and renal failure. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2010, 4, 190-196.	1.8	0
630	A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2727-2735.	1.2	202

#	ARTICLE	IF	CITATIONS
631	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	1.2	1,058
632	Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. <i>American Heart Journal</i> , 2010, 159, 871-875.	1.2	51
633	Body mass index and bleeding complications after percutaneous coronary intervention: Does bivalirudin make a difference?. <i>American Heart Journal</i> , 2010, 159, 1139-1146.	1.2	35
634	Novel antiplatelet therapy. <i>American Heart Journal</i> , 2010, 160, 595-604.	1.2	19
635	Drug-Eluting Balloon. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 352-358.	1.4	128
636	Outcome Differences With the Use of Drug-Eluting Stents for the Treatment of In-Stent Restenosis of Bare-Metal Stents Versus Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2009, 103, 491-495.	0.7	90
637	Prognostic Significance of Small Troponin I Rise After a Successful Elective Percutaneous Coronary Intervention of a Native Artery. <i>American Journal of Cardiology</i> , 2009, 103, 639-645.	0.7	36
638	Temporal Relation Between Clopidogrel Cessation and Stent Thrombosis After Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2009, 103, 801-805.	0.7	61
639	Incidence, Predictors, and Outcome of New, Subsequent Lesions Treated With Percutaneous Coronary Intervention in Patients Presenting With Myocardial Infarction. <i>American Journal of Cardiology</i> , 2009, 103, 1189-1195.	0.7	17
640	Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 104, 525-530.	0.7	54
641	Effects of Percutaneous Aortic Valve Replacement on Coronary Blood Flow Assessed With Transesophageal Doppler Echocardiography in Patients With Severe Aortic Stenosis. <i>American Journal of Cardiology</i> , 2009, 104, 850-855.	0.7	16
642	Definition, Incidence, Correlates, and Clinical Impact of "Nuisance" Bleeding in Patients Undergoing Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2009, 104, 30C-33C.	0.7	5
643	Effect of Drug-Eluting Stents on Frequency of Repeat Revascularization in Patients With Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2009, 104, 1654-1659.	0.7	15
644	The predictive value of computed tomography calcium scores: a comparison with quantitative volumetric intravascular ultrasound. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 30-35.	0.3	9
645	Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 156-161.	0.3	18
646	Effects of exogenous peripheral-blood-derived endothelial progenitor cells or unfractionated bone-marrow-derived cells on neointimal formation and inflammation in cholesterol-fed, balloon-denuded, and radiated iliac arteries of inbred rabbits. <i>Cardiovascular Revascularization Medicine</i> , 2009, 10, 110-116.	0.3	5
647	Prognostic value of the syntax score in patients undergoing coronary artery bypass grafting for three-vessel coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 612-617.	0.7	52
648	Paclitaxel-eluting balloon: From bench to bed. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 643-652.	0.7	58

#	ARTICLE	IF	CITATIONS
649	Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 428-435.	0.7	19
650	Attenuated Plaque Detected by Intravascular Ultrasound. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 65-72.	1.1	117
651	Impact of Bivalirudin Use on Outcomes in Nonagenarians Undergoing Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2009, 22, 61-67.	0.5	10
652	Clinical Manifestation and Prognosis of Early versus Late Stent Thrombosis of Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2009, 22, 228-233.	0.5	10
653	Early- and Long-Term Intravascular Ultrasound and Angiographic Findings After Bioabsorbable Magnesium Stent Implantation in Human Coronary Arteries. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 312-320.	1.1	170
654	Safety and Efficacy of Drug-Eluting and Bare Metal Stents. <i>Circulation</i> , 2009, 119, 3198-3206.	1.6	794
655	Prognostic value of procedure-related myocardial infarction according to the universal definition of myocardial infarction in saphenous vein graft interventions. <i>American Heart Journal</i> , 2009, 157, 894-898.	1.2	12
656	Response to "Myocardial infarction in saphenous percutaneous intervention: Are we really doing our best?". <i>American Heart Journal</i> , 2009, 158, e41.	1.2	0
657	The clinical significance of hematocrit values before and after percutaneous coronary intervention. <i>American Heart Journal</i> , 2009, 158, 1024-1030.	1.2	22
658	Intravascular ultrasound-guided percutaneous coronary interventions in contemporary practice. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 143-151.	0.7	12
659	Disease Progression in Nonintervened Saphenous Vein Graft Segments. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1257-1264.	1.2	18
660	Current state of the absorbable metallic (magnesium) stent. <i>EuroIntervention</i> , 2009, 5, F94-F97.	1.4	20
661	Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. <i>EuroIntervention</i> , 2009, 5, F36-F42.	1.4	11
662	Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. <i>EuroIntervention</i> , 2009, 4, 481-484.	1.4	61
663	The 5 Ts of Bifurcation Intervention: Type, Technique, Two Stents, T-Stenting, Trials. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 366-368.	1.1	12
664	Can direct stenting in selected saphenous vein graft lesions be considered an alternative to percutaneous intervention with a distal protection device?. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 799-803.	0.7	24
665	Short-Term Effects of Biocorrosible Iron Stents in Porcine Coronary Arteries. <i>Journal of Interventional Cardiology</i> , 2008, 21, 15-20.	0.5	211
666	Effect of Clopidogrel on Neointimal Formation and Inflammation in Balloon-Denuded and Radiated Hypercholesterolemic Rabbit Iliac Arteries. <i>Journal of Interventional Cardiology</i> , 2008, 21, 122-128.	0.5	15

#	ARTICLE	IF	CITATIONS
667	Vascular Brachytherapy for Patients with Drug-Eluting Stent Restenosis. <i>Journal of Interventional Cardiology</i> , 2008, 21, 528-534.	0.5	15
668	Outcomes After Sirolimus- and Paclitaxel-Eluting Stent Implantation in Patients With Insulin-Treated Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 101, 1253-1258.	0.7	19
669	Incidence, Predictors, and Outcomes of Post-Percutaneous Coronary Intervention Nephropathy in Patients With Diabetes Mellitus and Normal Baseline Serum Creatinine Levels. <i>American Journal of Cardiology</i> , 2008, 101, 1544-1549.	0.7	27
670	Bleeding Risk and Outcomes of Bivalirudin Versus Glycoprotein IIb/IIIa Inhibitors With Targeted Low-Dose Unfractionated Heparin in Patients Having Percutaneous Coronary Intervention for Either Stable or Unstable Angina Pectoris. <i>American Journal of Cardiology</i> , 2008, 102, 160-164.	0.7	20
671	Bivalirudin With Provisional Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Angioplasty in the Setting of Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2008, 102, 287-291.	0.7	21
672	Two-Year Outcome of Patients Treated With Sirolimus- Versus Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease (from the REWARDS Registry). <i>American Journal of Cardiology</i> , 2008, 102, 292-297.	0.7	13
673	Observations and Outcomes of Definite and Probable Drug-Eluting Stent Thrombosis Seen at a Single Hospital in a Four-Year Period. <i>American Journal of Cardiology</i> , 2008, 102, 298-303.	0.7	48
674	Impact of Optimal Medical Therapy and Revascularization on Outcome of Patients With Chronic Kidney Disease and on Dialysis Who Presented With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 102, 535-540.	0.7	40
675	Drug-Eluting Stents Versus Bare Metal Stents for Narrowing in Saphenous Vein Grafts. <i>American Journal of Cardiology</i> , 2008, 102, 530-534.	0.7	42
676	Comparison of Safety, Efficacy, and Outcome of Successful Versus Unsuccessful Percutaneous Coronary Intervention in Chronic Total Occlusions. <i>American Journal of Cardiology</i> , 2008, 102, 1175-1181.	0.7	64
677	Impact of Nuisance Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2008, 102, 1614-1617.	0.7	121
678	Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2008, 9, 24-28.	0.3	17
679	Optical coherence tomography and intravascular ultrasound imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries. <i>Cardiovascular Revascularization Medicine</i> , 2008, 9, 248-254.	0.3	63
680	PhotoPoint Photodynamic Therapy Promotes Stabilization of Atherosclerotic Plaques and Inhibits Plaque Progression. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1024-1032.	1.2	70
681	Stent thrombosis in 2008: Definition, predictors, prognosis and treatment. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 769-777.	0.7	49
682	Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents. <i>International Journal of Cardiology</i> , 2008, 125, 11-15.	0.8	19
683	Drug-eluting stents: is new necessarily better?. <i>Lancet</i> , The, 2008, 372, 1126-1128.	6.3	5
684	The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. <i>European Heart Journal</i> , 2008, 29, 1851-1857.	1.0	265

#	ARTICLE	IF	CITATIONS
685	Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent. <i>Circulation</i> , 2008, 117, 1603-1608.	1.6	23
686	Drug-Eluting Stents in Preclinical Studies. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 143-153.	1.4	197
687	Intracoronary brachytherapy. , 2008, , 197-217.		1
688	Drug-Eluting Stent Thrombosis vs Bare Metal Stent Restenosis: Finding the Lesser of Two Evils. <i>The American Heart Hospital Journal</i> , 2007, 5, 151-154.	0.2	1
689	Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug-Eluting Stents for Patients With Multivessel Coronary Artery Disease. <i>Circulation</i> , 2007, 116, 1200-6.	1.6	134
690	Cell therapy in myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 43-51.	0.3	32
691	ACUITY-PCI: one drug does not fit all. <i>Lancet, The</i> , 2007, 369, 881-882.	6.3	20
692	Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. <i>Lancet, The</i> , 2007, 369, 1869-1875.	6.3	803
693	Brachytherapy. , 2007, , 307-332.		1
694	Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 9-14.	0.7	53
695	Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 167-172.	0.7	8
696	Promise and challenges of bioabsorbable stents. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 407-414.	0.7	66
697	Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 1064-1074.	0.7	62
698	Does creatine kinase-MB (CK-MB) isoenzyme elevation following percutaneous coronary intervention with drug-eluting stents impact late clinical outcome?. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 826-831.	0.7	8
699	Late stent thrombosisâ€”The â€œvulnerableâ€•stent. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 54-56.	0.7	4
700	Efficacy and Safety of Absorbable Metallic Stents with Adjunct Intracoronary Beta Radiation in Porcine Coronary Arteries. <i>Journal of Interventional Cardiology</i> , 2007, 20, 367-372.	0.5	31
701	Angiographic and Procedural Correlates of Stent Thrombosis after Intracoronary Implantation of Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2007, 20, 307-313.	0.5	30
702	Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries. <i>Cardiovascular Revascularization Medicine</i> , 2007, 8, 259-274.	0.3	9

#	ARTICLE	IF	CITATIONS
703	Comparison of Effectiveness of Bare Metal Stents Versus Drug-Eluting Stents in Large (≥3.5 mm) Coronary Arteries. <i>American Journal of Cardiology</i> , 2007, 99, 599-602.	0.7	55
704	Long-Term Clinical Outcomes and Thrombosis Rates of Sirolimus-Eluting Versus Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease (REWARDS Registry). <i>American Journal of Cardiology</i> , 2007, 100, 45-51.	0.7	59
705	Intravascular Ultrasound Parameters Associated With Stent Thrombosis After Drug-Eluting Stent Deployment. <i>American Journal of Cardiology</i> , 2007, 100, 615-620.	0.7	154
706	Impact of In-Stent Restenosis on Death and Myocardial Infarction. <i>American Journal of Cardiology</i> , 2007, 100, 1109-1113.	0.7	20
707	Introduction. <i>American Journal of Cardiology</i> , 2007, 100, S1-S2.	0.7	0
708	Systemic Nanoparticle Paclitaxel (nab-Paclitaxel) for In-stent Restenosis I (SNAPIST-I): A First-in-Human Safety and Dose-finding Study. <i>Clinical Cardiology</i> , 2007, 30, 165-170.	0.7	81
709	Role of systemic antirestenotic drugs and results of current clinical trials. , 2007, , 185-194.		0
710	Stenting the vulnerable plaque. , 2007, , 437-443.		0
711	Comparative intravascular ultrasound analysis of ostial disease in the left main versus the right coronary artery. <i>Journal of Invasive Cardiology</i> , 2007, 19, 377-80.	0.4	10
712	IVUS-based dosimetry on patients with repeat-radiated coronary arteries to the same site. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 70-75.	0.3	0
713	Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 132-135.	0.3	11
714	Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 179-184.	0.3	23
715	Bone marrow-derived stem cell interactions with adult cardiomyocytes and skeletal myoblasts in vitro. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 222-230.	0.3	13
716	Comparison of paclitaxel-eluting stent and sirolimus-eluting stent expansion at incremental delivery pressures. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 208-211.	0.3	21
717	Peroxisome Proliferator-Activated Receptor γ Ligand Pioglitazone Alters Neointimal Composition in a Balloon-Denuded and Radiated Hypercholesterolemic Rabbit. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 48, 299-305.	0.8	22
718	Efficacy of Sirolimus-Eluting Stents as Compared to Paclitaxel-Eluting Stents for Saphenous Vein Graft Intervention. <i>Journal of Interventional Cardiology</i> , 2006, 19, 121-125.	0.5	25
719	Update on Bioabsorbable Stents: From Bench to Clinical. <i>Journal of Interventional Cardiology</i> , 2006, 19, 414-421.	0.5	84
720	Efficacy of Sirolimus-Eluting Stents Compared With Bare Metal Stents for Saphenous Vein Graft Intervention. <i>American Journal of Cardiology</i> , 2006, 97, 34-37.	0.7	77

#	ARTICLE	IF	CITATIONS
721	Impact of Three or More Versus a Single Sirolimus-Eluting Stent on Outcomes in Patients Who Undergo Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 97, 606-610.	0.7	13
722	Safety and Feasibility of Transendocardial Autologous Bone Marrow Cell Transplantation in Patients With Advanced Heart Disease. <i>American Journal of Cardiology</i> , 2006, 97, 823-829.	0.7	128
723	An Intravascular Ultrasound Analysis of the Mechanisms of Restenosis Comparing Drug-Eluting Stents With Brachytherapy. <i>American Journal of Cardiology</i> , 2006, 97, 1292-1298.	0.7	23
724	Comparison of Effectiveness and Safety of Drug-Eluting Stents Versus Vascular Brachytherapy for Saphenous Vein Graft In-Stent Restenosis. <i>American Journal of Cardiology</i> , 2006, 97, 1303-1307.	0.7	13
725	Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in the Treatment of Coronary Artery Disease in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2006, 98, 187-192.	0.7	38
726	Procedural Results and Outcomes After Extensive Stent Coverage With Drug-Eluting Stent Implantation in Single Coronary Lesions. <i>American Journal of Cardiology</i> , 2006, 98, 357-361.	0.7	4
727	Comparison of Outcomes Between Bare Metal Stents and Drug-Eluting Stents for Percutaneous Revascularization of Internal Mammary Grafts. <i>American Journal of Cardiology</i> , 2006, 98, 722-724.	0.7	19
728	Impact of Low High-Density Lipoproteins on In-Hospital Events and One-Year Clinical Outcomes in Patients With Nonâ€“ST-Elevation Myocardial Infarction Acute Coronary Syndrome Treated With Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2006, 98, 711-717.	0.7	72
729	Management and Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 98, 911-914.	0.7	169
730	Intravascular Brachytherapy Versus Drug-Eluting Stents for the Treatment of Patients With Drug-Eluting Stent Restenosis. <i>American Journal of Cardiology</i> , 2006, 98, 1340-1344.	0.7	61
731	Comparison of Clinical Outcomes of Overlapping Sirolimus- Versus Paclitaxel-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2006, 98, 1563-1566.	0.7	12
732	Sirolimus-eluting stents and calcified coronary lesions: Clinical outcomes of patients treated with and without rotational atherectomy. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 873-878.	0.7	92
733	Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 595-599.	0.7	21
734	A novel paclitaxel-eluting porous carbonâ€“carbon nanoparticle coated, nonpolymeric cobaltâ€“chromium stent: Evaluation in a porcine model. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 698-702.	0.7	64
735	Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 607-617.	0.7	287
736	Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 62-66.	0.7	3
737	Percutaneous coronary intervention with drug-eluting stents in octogenarians: Characteristics, clinical presentation, and outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 36-43.	0.7	41
738	Response to Letter Regarding Article, â€œCorrelates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis with Sirolimus- and Paclitaxel-Eluting Stentsâ€• <i>Circulation</i> , 2006, 114, .	1.6	0

#	ARTICLE	IF	CITATIONS
739	Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents. <i>Circulation</i> , 2006, 113, 1108-1113.	1.6	585
740	Biodegradable stents: they do their job and disappear. <i>Journal of Invasive Cardiology</i> , 2006, 18, 70-4.	0.4	92
741	Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. <i>Journal of Invasive Cardiology</i> , 2006, 18, 273-7.	0.4	47
742	Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH—a multicenter clinical trial. <i>Journal of Invasive Cardiology</i> , 2006, 18, 370-5.	0.4	15
743	Rapamycin Attenuates Atherosclerotic Plaque Progression in Apolipoprotein E Knockout Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 481-486.	0.8	96
744	Impact of Treatment of Coronary Artery Disease With Sirolimus-Eluting Stents on Outcomes of Diabetic and Nondiabetic Patients. <i>American Journal of Cardiology</i> , 2005, 96, 1100-1106.	0.7	24
745	Real-world clinical practice of intracoronary radiation therapy as compared to investigational trials. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 64, 61-66.	0.7	1
746	Underexpansion of sirolimus-eluting stents: Incidence and relationship to delivery pressure. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 222-226.	0.7	45
747	Three-year follow-up after intravascular \hat{I}^3 -radiation for in-stent restenosis in saphenous vein grafts. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 257-262.	0.7	5
748	Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 469-472.	0.7	24
749	Mysteries behind stent struts. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 254-256.	0.7	0
750	Selective versus exclusive use of sirolimus-eluting stent implantation in multivessel coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 473-477.	0.7	5
751	Contemporary use of drug-eluting stents. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 35-46.	0.4	7
752	Effect of Antioxidants on Atherosclerotic Plaque Formation in Balloon-Denuded and Irradiated Hypercholesterolemic Rabbits. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 540-547.	0.8	19
753	Intracoronary radiation therapy using a novel beta emitter for in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 52-57.	0.3	2
754	Drug-eluting stents for the treatment of in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 38-43.	0.3	14
755	Optimizing dosimetry with high-dose intracoronary gamma radiation (21 Gy) for patients with diffuse in-stent restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 108-112.	0.3	10
756	MRI evaluation of a coronary artery perforation. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 44-45.	0.3	1

#	ARTICLE	IF	CITATIONS
757	Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 154-159.	0.3	5
758	Impact of vessel calcification on outcomes after coronary stenting. <i>Cardiovascular Revascularization Medicine</i> , 2005, 6, 147-153.	0.3	104
759	Brachytherapy and bivalirudin evaluation study. <i>American Heart Journal</i> , 2005, 150, 832-837.	1.2	6
760	Drug-eluting stents versus repeat vascular brachytherapy for patients with recurrent in-stent restenosis after failed intracoronary radiation. <i>Journal of Invasive Cardiology</i> , 2005, 17, 659-62.	0.4	14
761	The Endeavor Stent System: will it be the new kid on the block? Numero uno, first among equals or equal?. <i>EuroIntervention</i> , 2005, 1, 123-4.	1.4	0
762	Preclinical Evaluation of Drug-Eluting Stents for Peripheral Applications. <i>Circulation</i> , 2004, 110, 2498-2505.	1.6	74
763	Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis. <i>Circulation</i> , 2004, 109, 340-344.	1.6	118
764	Usefulness of periprocedural creatinine phosphokinase-MB release to predict adverse outcomes after intracoronary radiation therapy for in-stent restenosis. <i>American Journal of Cardiology</i> , 2004, 93, 313-317.	0.7	13
765	Impact of major side branch on periprocedural enzyme elevation and long-term outcome in patients undergoing percutaneous coronary intervention and brachytherapy for in-stent restenosis. <i>American Journal of Cardiology</i> , 2004, 93, 1394-1397.	0.7	3
766	Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 94, 789-792.	0.7	26
767	Angiographic and clinical outcomes of late total occlusion versus treatment failure without late total occlusion in patients after intracoronary radiation therapy for in-stent restenosis. <i>American Journal of Cardiology</i> , 2004, 94, 1551-1554.	0.7	3
768	Impact of intravascular ultrasound-guided direct stenting on clinical outcome of patients treated for native coronary disease. <i>Cardiovascular Radiation Medicine</i> , 2004, 5, 15-19.	0.7	6
769	Peroxisome proliferator-activated receptor γ . <i>Cardiovascular Radiation Medicine</i> , 2004, 5, 44-48.	0.7	9
770	Effect of ionizing radiation on the stability and performance of the TAXUS Express2 paclitaxel-eluting stent. <i>Cardiovascular Radiation Medicine</i> , 2004, 5, 136-141.	0.7	6
771	Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents. <i>Cardiovascular Radiation Medicine</i> , 2004, 5, 64-70.	0.7	6
772	Hybrid approach for the treatment of a giant left main coronary artery aneurysm. <i>Cardiovascular Radiation Medicine</i> , 2004, 5, 153-154.	0.7	0
773	Transepical autologous bone marrow-derived mononuclear cell therapy in a porcine model of chronically infarcted myocardium. <i>Cardiovascular Radiation Medicine</i> , 2004, 5, 125-131.	0.7	24
774	Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. <i>Cardiovascular Radiation Medicine</i> , 2004, 5, 173-176.	0.7	17

#	ARTICLE	IF	CITATIONS
775	Effects of gamma radiation on the noninjured and unprotected left main. Catheterization and Cardiovascular Interventions, 2004, 61, 477-481.	0.7	1
776	Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 61, 354-359.	0.7	3
777	Use of IIb/IIIa inhibitors in patients with in-stent restenosis treated with intracoronary γ -radiation: Integrilin WRIST. Catheterization and Cardiovascular Interventions, 2004, 62, 162-166.	0.7	4
778	Bivalirudin-associated intracoronary thrombosis during γ -brachytherapy and its experimental validation in acute swine model. Catheterization and Cardiovascular Interventions, 2004, 62, 209-213.	0.7	5
779	Vascular complications following coronary intervention correlate with long-term cardiac events. Catheterization and Cardiovascular Interventions, 2004, 62, 181-185.	0.7	15
780	Favorable effect of γ -radiation for in-stent restenosis: Effect of diabetes on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 62, 303-307.	0.7	2
781	Impact of radiation dose on late clinical outcome after intracoronary radiation therapy: Three-year follow-up of Long WRIST. Catheterization and Cardiovascular Interventions, 2004, 62, 318-322.	0.7	4
782	Effects of contrast media on porcine bone marrow-derived mononuclear cells and calf myoblast viability and secretion of VEGF and MCP-1. Catheterization and Cardiovascular Interventions, 2004, 62, 476-481.	0.7	0
783	Vascular brachytherapy vs. drug-eluting stents for the treatment of in-stent restenosis: The jury's still out. Catheterization and Cardiovascular Interventions, 2004, 62, 290-291.	0.7	4
784	Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions. Journal of the American College of Cardiology, 2004, 44, 1386-1392.	1.2	28
785	Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis. Drugs, 2004, 64, 2379-2388.	4.9	18
786	Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, The, 2004, 364, 1519-1521.	6.3	1,338
787	Antioxidants attenuate atherosclerotic plaque development in a balloon-denuded and γ -radiated hypercholesterolemic rabbit. Cardiovascular Radiation Medicine, 2003, 4, 25-28.	0.7	9
788	Acute procedural complications and in-hospital events after percutaneous coronary interventions. Cardiovascular Radiation Medicine, 2003, 4, 12-17.	0.7	5
789	Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovascular Radiation Medicine, 2003, 4, 34-38.	0.7	34
790	Bone marrow and bone marrow derived mononuclear stem cells therapy for the chronically ischemic myocardium. Cardiovascular Radiation Medicine, 2003, 4, 164-168.	0.7	21
791	Beta emitter systems and results from clinical trials. Cardiovascular Radiation Medicine, 2003, 4, 54-63.	0.7	9
792	A case of Cypher restenosis treated with gamma radiation. Cardiovascular Radiation Medicine, 2003, 4, 169-170.	0.7	2

#	ARTICLE	IF	CITATIONS
793	Radiation-Induced Atherosclerotic Plaque Progression in a Hypercholesterolemic Rabbit. <i>Cardiovascular Radiation Medicine</i> , 2003, 4, 146-151.	0.7	33
794	Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 intervention. <i>American Journal of Cardiology</i> , 2003, 92, 1080-1083.	0.7	17
795	Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. <i>American Journal of Cardiology</i> , 2003, 92, 1409-1413.	0.7	27
796	Comparison of intracoronary gamma radiation for in-stent restenosis in saphenous vein grafts versus native coronary arteries. <i>American Journal of Cardiology</i> , 2003, 91, 22-26.	0.7	7
797	Usefulness of gamma intracoronary radiation for totally occluded in-stent restenotic coronary narrowing. <i>American Journal of Cardiology</i> , 2003, 91, 595-597.	0.7	5
798	Serial volumetric intravascular ultrasound assessment of native coronary artery versus saphenous vein grafts in-stent restenosis lesions after conventional catheter-based treatment. <i>American Journal of Cardiology</i> , 2003, 91, 739-741.	0.7	2
799	Feasibility and efficacy of tandem positioning on angiographic and clinical outcomes in the Intimal Hyperplasia Inhibition With Beta In-Stent Trial. <i>American Journal of Cardiology</i> , 2003, 91, 1113-1115.	0.7	2
800	Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial. <i>American Journal of Cardiology</i> , 2003, 91, 1261-1265.	0.7	7
801	Usefulness of beta radiation for de novo and In-Stent restenotic lesions in saphenous vein grafts. <i>American Journal of Cardiology</i> , 2003, 92, 312-314.	0.7	16
802	Comparison of creatine kinase elevation and outcome of comparison of percutaneous coronary intervention for saphenous vein graft in-stent restenosis versus de novo stenosis. <i>American Journal of Cardiology</i> , 2003, 92, 980-983.	0.7	5
803	Impact of intracoronary radiation on in-stent restenosis involving ostial lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 175-180.	0.7	4
804	Late thrombosis after gamma-brachytherapy. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 455-458.	0.7	11
805	Use of restenting should be minimized with intracoronary radiation therapy for in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 1-5.	0.7	9
806	Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 59, 338-343.	0.7	145
807	Understanding and Preventing the Edge Effect. <i>Journal of Interventional Cardiology</i> , 2003, 16, 1-7.	0.5	4
808	Late Thrombosis: A Problem Solved. <i>Journal of Interventional Cardiology</i> , 2003, 16, 9-13.	0.5	1
809	Vascular Brachytherapy: Is It Still a Viable Option?. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, P79-P83.	0.2	0
810	The outcome of percutaneous coronary intervention in patients with In-Stentrestenosis who failed intracoronary radiation therapy. <i>Journal of the American College of Cardiology</i> , 2003, 41, 551-556.	1.2	22

#	ARTICLE	IF	CITATIONS
811	Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1725-1731.	1.2	10
812	Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1721-1724.	1.2	392
813	Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study. <i>American Heart Journal</i> , 2003, 146, 142-145.	1.2	9
814	Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. <i>American Heart Journal</i> , 2003, 146, 501-506.	1.2	67
815	Coronary Brachytherapy in the Drug-Eluting Stent Era. <i>Circulation</i> , 2003, 108, 386-388.	1.6	24
816	Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions. <i>Circulation</i> , 2003, 107, 1744-1749.	1.6	100
817	Predictors of Subacute Stent Thrombosis. <i>Circulation</i> , 2003, 108, 43-47.	1.6	459
818	Time Course of Stent Endothelialization After Intravascular Radiation Therapy in Rabbit Iliac Arteries. <i>Circulation</i> , 2003, 107, 2153-2158.	1.6	44
819	Repeat Intracoronary Radiation for Recurrent In-Stent Restenosis in Patients Who Failed Intracoronary Radiation. <i>Circulation</i> , 2003, 108, 654-656.	1.6	29
820	Review of intracoronary radiation for in-stent restenosis. <i>Journal of Invasive Cardiology</i> , 2003, 15 Suppl A, 2A-8A.	0.4	2
821	Incidence, Morphology, Angiographic Findings, and Outcomes of Intramural Hematomas After Percutaneous Coronary Interventions. <i>Circulation</i> , 2002, 105, 2037-2042.	1.6	90
822	Radioactive 133-Xenon Gas-Filled Balloon to Prevent Restenosis. <i>Circulation</i> , 2002, 106, 725-729.	1.6	5
823	Twelve Versus Six Months of Clopidogrel to Reduce Major Cardiac Events in Patients Undergoing β -Radiation Therapy for In-Stent Restenosis. <i>Circulation</i> , 2002, 106, 776-778.	1.6	130
824	Intravascular Gamma Radiation for In-Stent Restenosis in Saphenous-Vein Bypass Grafts. <i>New England Journal of Medicine</i> , 2002, 346, 1194-1199.	13.9	140
825	How to Fix the Edge Effect of Catheter-Based Radiation Therapy in Stented Arteries. <i>Circulation</i> , 2002, 106, 2271-2277.	1.6	26
826	Drug-Eluting Stents in Preclinical Studies. <i>Circulation</i> , 2002, 106, 1867-1873.	1.6	271
827	Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. <i>Journal of the American College of Cardiology</i> , 2002, 39, 274-280.	1.2	115
828	The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?. <i>Journal of the American College of Cardiology</i> , 2002, 39, 578-584.	1.2	596

#	ARTICLE	IF	CITATIONS
829	The impact of lesion length and reference vessel diameter on angiographic restenosis and target vessel revascularization in treating in-stent restenosis with radiation. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1290-1296.	1.2	23
830	The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1930-1936.	1.2	41
831	Morphologic and angiographic features of coronary plaque rupture detected by intravascular ultrasound. <i>Journal of the American College of Cardiology</i> , 2002, 40, 904-910.	1.2	333
832	Use of localised intracoronary 125 I radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. <i>Lancet</i> , The, 2002, 359, 551-557.	6.3	291
833	Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. <i>American Journal of Cardiology</i> , 2002, 89, 54-57.	0.7	61
834	Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	20
835	Relation of residual stenosis after angioplasty to long-term outcome of patients treated for in-stent restenosis with intravascular radiation therapy. <i>American Journal of Cardiology</i> , 2002, 89, 1426-1428.	0.7	3
836	Intravascular ultrasound analysis of the impact of gamma radiation therapy on the treatment of saphenous vein graft in-stent restenosis. <i>American Journal of Cardiology</i> , 2002, 90, 1378-1381.	0.7	1
837	Editorial Note 3:1. <i>Cardiovascular Radiation Medicine</i> , 2002, 3, 1.	0.7	3
838	The cost-effectiveness of 125 I-radiation therapy for treatment of in-stent restenosis. <i>Cardiovascular Radiation Medicine</i> , 2002, 3, 107-113.	0.7	4
839	The initial course of in-stent restenosis influences the response to vascular brachytherapy. <i>Cardiovascular Radiation Medicine</i> , 2002, 3, 102-106.	0.7	1
840	The proximal location of stenosis in the left anterior descending coronary artery is not a predictive factor of worse outcome in the era of stent. <i>Cardiovascular Radiation Medicine</i> , 2002, 3, 127-132.	0.7	3
841	Drug-eluting stents. <i>Cardiovascular Radiation Medicine</i> , 2002, 3, 226-241.	0.7	34
842	A case of refractory in-stent restenosis: Failed RE-WRIST. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 57, 72-74.	0.7	3
843	Elderly patients have a favorable outcome after intracoronary radiation for in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 56, 466-471.	0.7	6
844	Balloon-based radiation therapy for treatment of in-stent restenosis in human coronary arteries: Results from the BRITE I study. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 57, 286-294.	0.7	14
845	The Wrist Series - What Have We Learnt?. <i>Herz</i> , 2002, 27, 23-29.	0.4	6
846	Localized intracoronary beta radiation therapy to inhibit recurrence of in-stent restenosis. <i>Clinical Research in Cardiology</i> , 2002, 91, 40-41.	1.2	8

#	ARTICLE	IF	CITATIONS
847	Effectiveness of radioactive tungsten source in the prevention of restenosis in stented porcine coronary arteries. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 252-262.	0.4	2
848	Vascular brachytherapy: applications in the era of drug-eluting stents. <i>Reviews in Cardiovascular Medicine</i> , 2002, 3 Suppl 5, S23-30.	0.5	1
849	Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1026-1030.	1.2	77
850	Intravascular Radiation Therapy after Balloon Angioplasty of Narrowed Femoropopliteal Arteries to Prevent Restenosis: Results of the PARIS Feasibility Clinical Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2001, 12, 915-921.	0.2	91
851	Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results. <i>American Heart Journal</i> , 2001, 141, 610-614.	1.2	44
852	Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 891-907.	1.9	21
853	A novel 32 P deployable balloon system inhibits formation of neointima in porcine coronary arteries after balloon-overstretching injury. <i>Coronary Artery Disease</i> , 2001, 12, 317-322.	0.3	3
854	Acute renal failure requiring dialysis after percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 52, 409-416.	0.7	219
855	Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 54, 295-300.	0.7	25
856	Intracoronary Beta Radiation: State of the Art. <i>Journal of Interventional Cardiology</i> , 2001, 14, 601-609.	0.5	6
857	Delayed re-endothelialization and T-cell infiltration following intracoronary radiation therapy in the porcine model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 495-501.	0.4	10
858	Serial intravascular ultrasound analysis of edge recurrence after intracoronary gamma radiation treatment of native artery in-stent restenosis lesions. <i>American Journal of Cardiology</i> , 2001, 87, 1145-1149.	0.7	17
859	Intravascular ultrasound assessment of the stenoses location and morphology in the left main coronary artery in relation to anatomic left main length. <i>American Journal of Cardiology</i> , 2001, 88, 1-4.	0.7	39
860	Two-year follow-up after beta and gamma intracoronary radiation therapy for patients with diffuse in-stent restenosis. <i>American Journal of Cardiology</i> , 2001, 88, 425-428.	0.7	48
861	Differential remodeling after balloon overstretch injury and either 125 I- or 137 Cs-intracoronary radiation of porcine coronary arteries. <i>Cardiovascular Radiation Medicine</i> , 2001, 2, 75-82.	0.7	9
862	Clinical trials of vascular brachytherapy for in-stent restenosis: update. <i>Cardiovascular Radiation Medicine</i> , 2001, 2, 107-113.	0.7	30
863	Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis. <i>Cardiovascular Radiation Medicine</i> , 2001, 2, 63-68.	0.7	15
864	Excimer laser coronary angioplasty and intracoronary radiation for in-stent restenosis: Six-month angiographic and clinical outcomes. <i>Cardiovascular Radiation Medicine</i> , 2001, 2, 191-196.	0.7	7

#	ARTICLE	IF	CITATIONS
865	Three-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. <i>Cardiovascular Radiation Medicine</i> , 2001, 2, 200-204.	0.7	28
866	Intravascular radiation accelerates atherosclerotic lesion formation of hypercholesteremic rabbits. <i>Cardiovascular Radiation Medicine</i> , 2001, 2, 231-240.	0.7	28
867	Edge Stenosis After Intracoronary Radiotherapy. <i>Circulation</i> , 2001, 103, 2219-2220.	1.6	7
868	Comparative Efficacy of $\hat{\text{I}}^3$ -Irradiation for Treatment of In-Stent Restenosis in Saphenous Vein Graft Versus Native Coronary Artery In-Stent Restenosis. <i>Circulation</i> , 2001, 104, 3020-3022.	1.6	18
869	Serial Intravascular Ultrasound Assessment of the Efficacy of Intracoronary $\hat{\text{I}}^3$ -Radiation Therapy for Preventing Recurrence in Very Long, Diffuse, In-Stent Restenosis Lesions. <i>Circulation</i> , 2001, 104, 856-859.	1.6	45
870	Serial Intravascular Ultrasound Analysis of the Impact of Lesion Length on the Efficacy of Intracoronary $\hat{\text{I}}^3$ -Irradiation for Preventing Recurrent In-Stent Restenosis. <i>Circulation</i> , 2001, 103, 188-191.	1.6	29
871	Prolonged Antiplatelet Therapy to Prevent Late Thrombosis After Intracoronary $\hat{\text{I}}^3$ -Radiation in Patients With In-Stent Restenosis. <i>Circulation</i> , 2001, 103, 2332-2335.	1.6	167
872	Late thrombosis following intracoronary brachytherapy. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 49, 344-347.	0.7	37
873	Late total occlusions following restenting for in-stent restenosis: To restent or not to restent?. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 49, 479b-480.	0.7	0
874	Intracoronary brachytherapy not associated with changes in major side branches. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 51, 154-158.	0.7	4
875	Incidence, management, and outcome of coronary artery perforation during percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2000, 86, 680-682.	0.7	161
876	Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. <i>American Journal of Cardiology</i> , 2000, 86, 777-779.	0.7	18
877	Safety of Intracoronary $\hat{\text{I}}^3$ -Radiation on Uninjured Reference Segments During the First 6 Months After Treatment of In-Stent Restenosis. <i>Circulation</i> , 2000, 101, 2227-2230.	1.6	24
878	Intracoronary $\hat{\text{I}}^2$ -Radiation Therapy Inhibits Recurrence of In-Stent Restenosis. <i>Circulation</i> , 2000, 101, 1895-1898.	1.6	304
879	Intracoronary $\hat{\text{I}}^3$ -Radiation Therapy After Angioplasty Inhibits Recurrence in Patients With In-Stent Restenosis. <i>Circulation</i> , 2000, 101, 2165-2171.	1.6	517
880	Treatment of In-Stent Restenosis With Excimer Laser Coronary Angioplasty Versus Rotational Atherectomy. <i>Circulation</i> , 2000, 101, 2484-2489.	1.6	140
881	$\hat{\text{I}}^2$ -Radiation to INHIBIT Recurrence of In-Stent Restenosis: Clinical and Angiographic Results of the Multicenter, Randomized, Double-Blind Study. <i>Circulation</i> , 2000, 102, .	1.6	22
882	Positive Remodeling, Regression of In-Stent Neointimal Hyperplasia, and Late Stent Malapposition in the Absence of Brachytherapy. <i>Circulation</i> , 2000, 102, E111.	1.6	3

#	ARTICLE	IF	CITATIONS
883	Inhibition of Restenosis With \hat{I}^2 -Emitting Radiotherapy. <i>Circulation</i> , 2000, 102, 951-958.	1.6	254
884	Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. <i>Journal of the American College of Cardiology</i> , 2000, 36, 65-68.	1.2	216
885	Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. <i>Journal of the American College of Cardiology</i> , 2000, 35, 389-397.	1.2	28
886	Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes. <i>Journal of the American College of Cardiology</i> , 2000, 35, 944-948.	1.2	57
887	Late Thrombosis After Radiation. <i>Circulation</i> , 1999, 100, 780-782.	1.6	170
888	Effects of Intracoronary Radiation on Thrombosis After Balloon Overstretch Injury in the Porcine Model. <i>Circulation</i> , 1999, 100, 2527-2533.	1.6	51
889	Fibrocellular tissue responses to endovascular and external beam irradiation in the porcine model of restenosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 633-641.	0.4	23
890	Vascular Brachytherapy: Are We Ready Yet?. <i>Journal of Interventional Cardiology</i> , 1999, 12, 233-234.	0.5	0
891	Intracoronary Irradiation with $^{186/188}\text{Re}$ Following Balloon Overstretch Injury Reduces Neointima But Does Not Impair Vasoreactivity of Porcine Coronary Arteries. <i>Journal of Interventional Cardiology</i> , 1999, 12, 263-270.	0.5	4
892	Vascular Brachytherapy for Prevention of Recurrence of In-stent Restenosis. <i>Journal of Interventional Cardiology</i> , 1999, 12, 305-312.	0.5	3
893	Surface Profile of the Internal Elastic Lamina May Modulate Thrombosis Following Intracoronary Radiation in Balloon-Injured Porcine Arteries. <i>Journal of Interventional Cardiology</i> , 1999, 12, 457-464.	0.5	1
894	Modulation of protein expression and activity by radiation. <i>Cardiovascular Radiation Medicine</i> , 1999, 1, 336-343.	0.7	1
895	Two-year follow-up after intracoronary gamma radiation therapy. <i>Cardiovascular Radiation Medicine</i> , 1999, 1, 30-35.	0.7	27
896	Intracoronary Radiation Post PTCA Prevents Late Arterial Constriction. <i>Journal of Interventional Cardiology</i> , 1998, 11, 535-541.	0.5	4
897	Intracoronary brachytherapy in the cath lab. <i>Herz</i> , 1998, 23, 401-406.	0.4	11
898	Endovascular \hat{I}^2 -Radiation to Reduce Restenosis After Coronary Balloon Angioplasty. <i>Circulation</i> , 1998, 97, 2025-2030.	1.6	342
899	Procedural Results and Late Clinical Outcomes After Placement of Three or More Stents in Single Coronary Lesions. <i>Circulation</i> , 1998, 97, 1355-1361.	1.6	61
900	Short- and long-term outcome of narrowed saphenous vein bypass graft: A comparison of Palmaz-Schatz stent, directional coronary atherectomy, and balloon angioplasty. <i>American Heart Journal</i> , 1997, 134, 274-281.	1.2	27

#	ARTICLE	IF	CITATIONS
901	Intracoronary Radiation Adjunct Therapy to Stenting. Journal of Interventional Cardiology, 1997, 10, 133-135.	0.5	1
902	Long-term Angiographic and Clinical Outcome After Percutaneous Transluminal Coronary Angioplasty and Intracoronary Radiation Therapy in Humans. Circulation, 1997, 96, 727-732.	1.6	289
903	Effect of Intravascular Irradiation on Cell Proliferation, Apoptosis, and Vascular Remodeling After Balloon Overstretch Injury of Porcine Coronary Arteries. Circulation, 1997, 96, 1944-1952.	1.6	143
904	Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. American Journal of Cardiology, 1996, 78, 221-224.	0.7	4
905	Myocardial infarction as a complication of new interventional devices. American Journal of Cardiology, 1996, 78, 751-756.	0.7	31
906	The role of the adventitia in the arterial response to angioplasty: The effect of intravascular radiation. International Journal of Radiation Oncology Biology Physics, 1996, 36, 789-796.	0.4	186
907	Predictors of groin complications after balloon and new-device coronary intervention. American Journal of Cardiology, 1995, 75, 886-889.	0.7	194
908	Distal embolization is common after directional atherectomy in coronary arteries and saphenous vein grafts. American Heart Journal, 1995, 129, 430-435.	1.2	13
909	Endovascular Low-Dose Irradiation Inhibits Neointima Formation After Coronary Artery Balloon Injury in Swine. Circulation, 1995, 91, 1533-1539.	1.6	305
910	Intracoronary Low-Dose I^{125} -Irradiation Inhibits Neointima Formation After Coronary Artery Balloon Injury in the Swine Restenosis Model. Circulation, 1995, 92, 3025-3031.	1.6	238
911	Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stented Porcine Coronary Arteries. Circulation, 1995, 92, 1383-1386.	1.6	157
912	Efficacy and safety of using perfusion dilatation catheter as initial balloon in coronary angioplasty. Catheterization and Cardiovascular Diagnosis, 1994, 32, 319-322.	0.7	2
913	The Pathobiology of CTO. , 0, , 1-7.		1
914	Streptokinase, Alteplase, Reteplase, or Tenecteplase. , 0, , 133-139.		0
915	Bilateral Approach. , 0, , 107-112.		1
916	Other Books Available from Wiley-Blackwell. , 0, , G1-G1.		0
917	Parallel-Wire Techniques. , 0, , 83-86.		2
918	Optimal Antithrombotic Therapy. , 0, , 1-9.		0

#	ARTICLE	IF	CITATIONS
919	Antithrombotic Therapy for Non ST-Elevation Acute Coronary Syndromes. , 0, , 79-92.		1
920	Oral Anticoagulation Issues in Percutaneous Coronary Intervention. , 0, , 158-164.		0
921	High-Risk Coronary Intervention and Renal Dysfunction. , 0, , 190-194.		0
922	Ideal Contrast Agent. , 0, , 210-215.		0
923	Clopidogrel Use in Patients Requiring Coronary Artery Bypass Grafting. , 0, , 257-260.		0
924	Introduction of a New 0.014-Inch CiTopâ„¢ Guidewire for CTO: Preclinical Safety and Feasibility Studies. , 0, , 62-69.		0
925	Frontrunner CTO Technology. , 0, , 70-73.		0
926	Use of Two Wires in the Treatment of CTO. , 0, , 75-82.		0
927	Wire Control Handling Technique. , 0, , 87-92.		0
928	Subintimal Angioplasty. , 0, , 93-103.		0
929	Re-Entry Techniqueâ€” Pioneer Catheter. , 0, , 104-106.		0
930	Tips and Tricks of the CART Technique. , 0, , 113-120.		0
931	Radio Frequency. , 0, , 121-135.		0
932	Indication and Outcome of PCI for CTO. , 0, , 8-13.		0
933	High-Frequency Mechanical Revascularization. , 0, , 136-139.		0
934	Debulking of CTO. , 0, , 140-144.		0
935	Vibrational Angioplasty. , 0, , 145-149.		0
936	Drug-Eluting Stents. , 0, , 150-158.		0

#	ARTICLE	IF	CITATIONS
937	Laser for CTO Recanalization. , 0, , 159-164.		0
938	How to Minimize Contrast Nephropathy. , 0, , 178-185.		0
939	Interesting Cases I, II. , 0, , 187-193.		0
940	CTOâ€“ Review of Trials. , 0, , 14-21.		0
941	CT Angiography: Application in Chronic Total Occlusions. , 0, , 23-31.		0
942	Magnetic Navigation Wire. , 0, , 32-37.		0
943	IVUS-Guided Recanalization of CTO. , 0, , 38-41.		0
944	Deflecting Tip Wires. , 0, , 43-49.		0
945	ASAHI Wires. , 0, , 50-56.		0
946	Tornus Catheter. , 0, , 57-61.		0